Trial Outcomes & Findings for ABSORB III Randomized Controlled Trial (RCT) (NCT NCT01751906)

NCT ID: NCT01751906

Last Updated: 2023-10-11

Results Overview

TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Recruitment status

COMPLETED

Study phase

Target enrollment

2008 participants

Primary outcome timeframe

1 year

Results posted on

2023-10-11

Participant Flow

The first Lead-In subject (Lead-In Group ) was registered on Dec 28, 2012. A total of 2008 patients (Primary Analysis Group) were randomized into Absorb BVS arm (n = 1322) and Xience arm (n = 686) at 193 study sites between March 22, 2013 \& April 3,2014 and the last 5 year follow-up visit was on May 31, 2019.

Of total 13,789 eligible population,11,781 patients were excluded due to, 1. Not meeting general eligibility criteria only (n=567); 2. Not meeting angiographic eligibility criteria only (n=10,690); 3. Not meeting both 1 and 2 (n=64); 4. Other reasons (n=460).

Participant milestones

Participant milestones
Measure	Absorb BVS Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Overall Study STARTED	1322	686
Overall Study COMPLETED	1059	555
Overall Study NOT COMPLETED	263	131

Reasons for withdrawal

Reasons for withdrawal
Measure	Absorb BVS Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Overall Study Lost to Follow-up	151	68
Overall Study Withdrawal by Subject	22	18
Overall Study Physician Decision	5	2
Overall Study Death	84	43
Overall Study Denied on premises for follow-up by law	1	0

Baseline Characteristics

The number of participants analyzed includes subjects who were available at that time of analysis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Absorb BVS n=1322 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=686 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	Total n=2008 Participants Total of all reporting groups
Age, Continuous	63.5 years STANDARD_DEVIATION 10.6 • n=1322 Participants	63.6 years STANDARD_DEVIATION 10.3 • n=686 Participants	63.5 years STANDARD_DEVIATION 10.5 • n=2008 Participants
Sex: Female, Male Female	388 Participants n=1322 Participants	205 Participants n=686 Participants	593 Participants n=2008 Participants
Sex: Female, Male Male	934 Participants n=1322 Participants	481 Participants n=686 Participants	1415 Participants n=2008 Participants
Race/Ethnicity, Customized Hispanic or Latino	50 Participants n=1322 Participants	23 Participants n=686 Participants	73 Participants n=2008 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	1250 Participants n=1322 Participants	652 Participants n=686 Participants	1902 Participants n=2008 Participants
Race/Ethnicity, Customized Unknown or not reported	22 Participants n=1322 Participants	11 Participants n=686 Participants	33 Participants n=2008 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	8 Participants n=1322 Participants	2 Participants n=686 Participants	10 Participants n=2008 Participants
Race/Ethnicity, Customized Asian	20 Participants n=1322 Participants	13 Participants n=686 Participants	33 Participants n=2008 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	8 Participants n=1322 Participants	1 Participants n=686 Participants	9 Participants n=2008 Participants
Race/Ethnicity, Customized Black or African American	70 Participants n=1322 Participants	34 Participants n=686 Participants	104 Participants n=2008 Participants
Race/Ethnicity, Customized White	1152 Participants n=1322 Participants	606 Participants n=686 Participants	1758 Participants n=2008 Participants
Region of Enrollment United States	1318 Participants n=1322 Participants	683 Participants n=686 Participants	2001 Participants n=2008 Participants
Region of Enrollment Australia	4 Participants n=1322 Participants	3 Participants n=686 Participants	7 Participants n=2008 Participants
Hypertension Requiring Medication	1071 Participants n=1322 Participants	553 Participants n=686 Participants	1624 Participants n=2008 Participants
Dyslipidemia Requiring Medication	1009 Participants n=1322 Participants	533 Participants n=686 Participants	1542 Participants n=2008 Participants
Prior Coronary Intervention	512 Participants n=1322 Participants • The number of participants analyzed includes subjects who were available at that time of analysis	260 Participants n=684 Participants • The number of participants analyzed includes subjects who were available at that time of analysis	772 Participants n=2006 Participants • The number of participants analyzed includes subjects who were available at that time of analysis
Stable Angina	757 Participants n=1321 Participants • The number of participants analyzed includes subjects who were available at that time of analysis	417 Participants n=686 Participants • The number of participants analyzed includes subjects who were available at that time of analysis	1174 Participants n=2007 Participants • The number of participants analyzed includes subjects who were available at that time of analysis

PRIMARY outcome

Timeframe: 1 year

Population: Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1313 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=677 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Cardiac Death/TV-MI/ID-TLR (TLF)	102 Participants	41 Participants

SECONDARY outcome

Timeframe: 1 year

Population: The analysis will exclude angina following the index procedure through discharge, not to exceed a period of 7 days. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Angina is defined as the first adverse event resulting in the site diagnosis of angina.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1303 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=678 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Powered Secondary Endpoint: Angina	238 Participants	125 Participants

SECONDARY outcome

Timeframe: 1 year

Population: ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through 1 year without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).

This powered secondary endpoint is intended to assess all revascularization at 1 year and test for superiority of Absorb BVS to XIENCE. All revascularizations are comprised of TLR, TVR excluding TLR, and non-TVR.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1313 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=677 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Powered Secondary Endpoint: All Revascularization	120 Participants	55 Participants

SECONDARY outcome

Timeframe: 1 year

Population: For ID-TVR, Fisher's exact test is used for superiority testing based on the ITT population. This analysis will include \~2000 subjects. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame

This powered secondary endpoint is intended to assess all ID-TVR at 1 year and test for superiority of Absorb BVS to XIENCE.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1313 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=677 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Powered Secondary Endpoint: Ischemia Driven Target Vessel Revascularization (ID-TVR)	66 Participants	25 Participants

SECONDARY outcome

Timeframe: On day 0 (the day of procedure)

Population: Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.

Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1355 Target Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=704 Target Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Acute Success- Device Success (Lesion Level Analysis)	94.3 Percentage of lesions	99.3 Percentage of lesions

SECONDARY outcome

Timeframe: On day 0 (the day of procedure)

Population: Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.

Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1311 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=678 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Acute Success: Procedural Success (Subject Level Analysis)	1240 Participants	652 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac. Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Death (Cardiac, Vascular, Non-cardiovascular)	85 Participants	44 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With All Myocardial Infarction (MI)	159 Participants	69 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography. The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With All Target Lesion Revascularization (TLR)	118 Participants	51 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)	108 Participants	40 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With All Revascularization	255 Participants	114 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Death/All MI	230 Participants	101 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Cardiac Death/All MI	185 Participants	81 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Cardiac Death/TV-MI/ID-TLR (TLF)	220 Participants	98 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)	245 Participants	113 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Target Vessel Failure (TVF)	290 Participants	128 Participants

SECONDARY outcome

Timeframe: 0 to 5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1187 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=612 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Death/All MI/All Revascularization (DMR)	378 Participants	168 Participants

SECONDARY outcome

Timeframe: ≤ 1 Day

Population: Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab. Timing : Acute : 0 - 24 hours post stent implantation; Subacute : \>24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : \>1 year post stent implantation. Evidence: Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1319 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=686 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Acute Stent/Scaffold Thrombosis (Per ARC Definition) Definite/Probable	3 Participants	4 Participants
Number of Participants With Acute Stent/Scaffold Thrombosis (Per ARC Definition) Definite	3 Participants	4 Participants
Number of Participants With Acute Stent/Scaffold Thrombosis (Per ARC Definition) Probable	0 Participants	0 Participants

SECONDARY outcome

Timeframe: 0 to 30 Days

Outcome measures

Outcome measures
Measure	Absorb BVS n=1314 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=686 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Acute/Subacute Stent/Scaffold Thrombosis (Per ARC Definition) Definite/Probable	14 Participants	5 Participants
Number of Participants With Acute/Subacute Stent/Scaffold Thrombosis (Per ARC Definition) Definite	12 Participants	5 Participants
Number of Participants With Acute/Subacute Stent/Scaffold Thrombosis (Per ARC Definition) Probable	2 Participants	0 Participants

SECONDARY outcome

Timeframe: >1 to 30 Days

Outcome measures

Outcome measures
Measure	Absorb BVS n=1314 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=686 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Subacute Stent/Scaffold Thrombosis Definite	10 Participants	1 Participants
Number of Participants With Subacute Stent/Scaffold Thrombosis Probable	2 Participants	0 Participants
Number of Participants With Subacute Stent/Scaffold Thrombosis Definite/Probable	12 Participants	1 Participants

SECONDARY outcome

Timeframe: 31 to 365 Days

Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab. Timing : Acute : 0 - 24 hours post stent implantation; Subacute : \>24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : \>1 year post stent implantation. Evidence: Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of * Any unexplained death within the first 30 days or * Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1289 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=672 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition) Definite/Probable	6 Participants	0 Participants
Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition) Definite	6 Participants	0 Participants
Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition) Probable	0 Participants	0 Participants

SECONDARY outcome

Timeframe: 366 to 393 Days

Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab. Timing : Acute : 0 - 24 hours post stent implantation; Subacute : \>24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : \>1 year post stent implantation. Evidence: Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of * Any unexplained death within the first 30 days or * Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1289 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=672 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Very Late Stent /Scaffold Thrombosis (Per ARC Definition) Definite/Probable	0 Participants	0 Participants
Number of Participants With Very Late Stent /Scaffold Thrombosis (Per ARC Definition) Definite	0 Participants	0 Participants
Number of Participants With Very Late Stent /Scaffold Thrombosis (Per ARC Definition) Probable	0 Participants	0 Participants

SECONDARY outcome

Timeframe: 0 to 1853 Days

Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab. Timing : Acute : 0 - 24 hours post stent implantation; Subacute : \>24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : \>1 year post stent implantation. Evidence: Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of * Any unexplained death within the first 30 days or * Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1072 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=558 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Number of Participants With Cumulative Stent/Scaffold Thrombosis Definite/Probable	32 Participants	7 Participants
Number of Participants With Cumulative Stent/Scaffold Thrombosis Definite	30 Participants	7 Participants
Number of Participants With Cumulative Stent/Scaffold Thrombosis Probable	2 Participants	0 Participants

SECONDARY outcome

Timeframe: < or = 1 day

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Angiographic endpoint Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1380 Target Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=708 Target Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Pre-Procedure Minimum Lumen Diameter (MLD)	0.92 Millimeter Standard Deviation 0.37	0.90 Millimeter Standard Deviation 0.34

SECONDARY outcome

Timeframe: < or = 1 day

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Percent Diameter Stenosis is defined as the value calculated as 100 \* (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1380 Target Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=708 Target Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Pre-Procedure Percent Diameter Stenosis (%DS)	65.25 Percent Diameter stenosis Standard Deviation 12.48	65.90 Percent Diameter stenosis Standard Deviation 11.66

SECONDARY outcome

Timeframe: ≤ 7 days post index procedure

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1374 Target Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=706 Target Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Post-Procedure In-Segment Minimum Lumen Diameter (MLD)	2.15 Millimeter Standard Deviation 0.41	2.14 Millimeter Standard Deviation 0.43

SECONDARY outcome

Timeframe: ≤ 7 days post index procedure

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Angiographic endpoint. Percent Diameter Stenosis is defined as the value calculated as 100 \* (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1374 Target Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=706 Target Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Post-Procedure In-Segment Percent Diameter Stenosis (%DS)	20.04 Percent Diameter stenosis Standard Deviation 7.94	19.82 Percent Diameter stenosis Standard Deviation 8.20

SECONDARY outcome

Timeframe: ≤ 7 days post index procedure

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1373 Target Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=706 Target Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Post-Procedure In-Device Minimum Lumen Diameter (MLD)	2.37 Millimeter Standard Deviation 0.40	2.49 Millimeter Standard Deviation 0.40

SECONDARY outcome

Timeframe: ≤ 7 days post index procedure

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1369 Target Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=702 Target Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Post-Procedure In-Device Percent Diameter Stenosis (%DS)	11.62 Percent Diameter stenosis Standard Deviation 8.77	6.41 Percent Diameter stenosis Standard Deviation 8.91

SECONDARY outcome

Timeframe: ≤ 7 days post index procedure

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

The acute gain was defined as the difference between post- and pre procedural minimal lumen diameter (MLD).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1372 Target Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=706 Target Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Post-Procedure In-Device Acute Gain	1.45 mm Standard Deviation 0.45	1.59 mm Standard Deviation 0.44

SECONDARY outcome

Timeframe: From Post procedure to 3 Years

Population: The full analysis set (FAS) population is defined as the patients wherein the target lesion was treated with the assigned device.

* Mean lumen area measured after nitrate infusions, superiority test, \~300 pooled subjects. * Pooled IVUS subjects (\~300 subjects): 150 subjects from the Imaging Cohort of ABSORB III RCT and 150 subjects from ABSORB Japan RCT.

Outcome measures

Outcome measures
Measure	Absorb BVS n=119 Lesions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=65 Lesions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Powered Imaging Cohort Secondary Endpoint: The Instent/Scaffold Mean Lumen Area Change, From Post Procedure to 3 Years by Intravascular Ultrasound (IVUS)	-0.30 mm^2 Standard Deviation 1.32	-0.60 mm^2 Standard Deviation 0.91

SECONDARY outcome

Timeframe: 3 Years

Population: The full analysis set (FAS) population is defined as the patients wherein the target lesion was treated with the assigned device

All OCT endpoints will be collected for within the device and within the treated segment: Descriptive analysis of strut, lesion and vessel morphology Mean neointimal area (NIA) - Apposed to the vessel wall with neointimal coverage Apposed to vessel wall without neointimal coverage Incomplete apposition to vessel wall with neointimal coverage Incomplete apposition to vessel wall without neointimal coverage Lumen area/volume stenosis % Mean/minimal device area Mean/minimal luminal area/volume Mean strut area/volume Persisting incomplete apposition, late incomplete apposition at 3 years (if analyzable) OCT analysis for subjects with jailed side branch Descriptive analyses from 3-dimensional OCT reconstructions

Outcome measures

Outcome measures
Measure	Absorb BVS n=21 Leisions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=10 Leisions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Optical Coherence Tomography (OCT) Endpoint: Mean Neointimal Area (NIA)	1.12 mm^2 Standard Deviation 0.48	1.19 mm^2 Standard Deviation 0.61

SECONDARY outcome

Timeframe: 3 Years

Population: The full analysis set (FAS) population is defined as the patients wherein the target lesion was treated with the assigned device.

Outcome measures

Outcome measures
Measure	Absorb BVS n=33 Leisions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=16 Leisions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Optical Coherence Tomography (OCT) Endpoint: Mean Device Area, Adluminal Post-procedure	6.89 mm^2 Standard Deviation 1.98	7.25 mm^2 Standard Deviation 1.51
Optical Coherence Tomography (OCT) Endpoint: Mean Device Area, Adluminal 3 Years	7.70 mm^2 Standard Deviation 2.54	7.24 mm^2 Standard Deviation 1.90

SECONDARY outcome

Timeframe: 3 Years

Population: The full analysis set (FAS) population is defined as the patients wherein the target lesion was treated with the assigned device.

Outcome measures

Outcome measures
Measure	Absorb BVS n=33 Leisions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=16 Leisions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Optical Coherence Tomography (OCT) Endpoint: Mean Lumen Area 3 Years	6.67 mm^2 Standard Deviation 2.36	6.06 mm^2 Standard Deviation 1.73
Optical Coherence Tomography (OCT) Endpoint: Mean Lumen Area Post-procedure	7.99 mm^2 Standard Deviation 2.12	7.50 mm^2 Standard Deviation 1.46

SECONDARY outcome

Timeframe: 3 Years

Population: The full analysis set (FAS) population is defined as the patients wherein the target lesion was treated with the assigned device.

Outcome measures

Outcome measures
Measure	Absorb BVS n=33 Leisions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=16 Leisions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Optical Coherence Tomography (OCT) Endpoint: Minimal Lumen Area Post-procedure	6.47 mm^2 Standard Deviation 1.82	6.07 mm^2 Standard Deviation 1.46
Optical Coherence Tomography (OCT) Endpoint: Minimal Lumen Area 3 Years	4.95 mm^2 Standard Deviation 1.78	4.54 mm^2 Standard Deviation 1.40

SECONDARY outcome

Timeframe: 3 Years

Population: The full analysis set (FAS) population is defined as the patients wherein the target lesion was treated with the assigned device.

Outcome measures

Outcome measures
Measure	Absorb BVS n=33 Leisions Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=16 Leisions Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Optical Coherence Tomography (OCT) Endpoint: Percentage of Malapposition Struts Post-procedure	7.42 Percentage of Malapposition Struts Standard Deviation 5.49	7.64 Percentage of Malapposition Struts Standard Deviation 6.26
Optical Coherence Tomography (OCT) Endpoint: Percentage of Malapposition Struts 3 Years	0.32 Percentage of Malapposition Struts Standard Deviation 0.99	0.07 Percentage of Malapposition Struts Standard Deviation 0.22

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Overall health status assessed using the EuroQoL 5D (EQ-5D™). EQ-5D: * Scale range: 0 to 1 * Higher values represent better outcomes * Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status. A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1

Outcome measures

Outcome measures
Measure	Absorb BVS n=1249 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=651 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Overall Health Status	0.77 score on a scale Standard Deviation 0.2	0.77 score on a scale Standard Deviation 0.20

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1231 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=647 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Overall Health Status	0.85 score on a scale Standard Deviation 0.18	0.85 score on a scale Standard Deviation 0.18

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 months

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1087 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=567 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Overall Health Status	0.83 score on a scale Standard Deviation 0.20	0.83 score on a scale Standard Deviation 0.19

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7). GAD-7: * Scale range: 0 to 21 * Lower values represent better outcomes * No subscales

Outcome measures

Outcome measures
Measure	Absorb BVS n=1009 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=530 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Anxiety	5.92 score on a scale Standard Deviation 5.86	6.34 score on a scale Standard Deviation 6.07

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7). GAD-7: * Scale range: 0 to 21 * Lower values represent better outcomes * No subscales

Outcome measures

Outcome measures
Measure	Absorb BVS n=1067 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=556 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Anxiety	3.39 score on a scale Standard Deviation 4.64	3.33 score on a scale Standard Deviation 4.61

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 months

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7). GAD-7: * Scale range: 0 to 21 * Lower values represent better outcomes * No subscales

Outcome measures

Outcome measures
Measure	Absorb BVS n=911 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=482 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Anxiety	3.92 score on a scale Standard Deviation 4.99	4.04 score on a scale Standard Deviation 5.08

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Disease-Specific quality of life assessed using the Seattle Angina Questionnaire (SAQ) Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1195 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=617 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Disease-Specific Quality of Life	67.67 score on a scale Standard Deviation 20.20	67.11 score on a scale Standard Deviation 19.17

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Disease-Specific quality of life in hospital baseline and at 1 year assessed using the Seattle Angina Questionnaire (SAQ). Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1131 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=589 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Disease-Specific Quality of Life	87.10 score on a scale Standard Deviation 14.27	86.98 score on a scale Standard Deviation 14.16

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 months

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1014 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=514 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Disease-Specific Quality of Life	87.05 score on a scale Standard Deviation 13.91	86.42 score on a scale Standard Deviation 14.45

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Dyspnea severity assessed using the Rose Dyspnea Scale (RDS). Rose Dyspnea Scale: * Scale range: 0 to 4 * Lower values represent better outcomes (higher scores indicate worse dyspnea) * No subscales

Outcome measures

Outcome measures
Measure	Absorb BVS n=1242 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=651 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Dyspnea Severity	1.66 score on a scale Standard Deviation 1.48	1.65 score on a scale Standard Deviation 1.46

OTHER_PRE_SPECIFIED outcome

Timeframe: 1 month

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Dyspnea severity assessed using the Rose Dyspnea Scale (RDS). Rose Dyspnea Scale: * Scale range: 0 to 4 * Lower values represent better outcomes (higher scores indicate worse dyspnea) * No subscales

Outcome measures

Outcome measures
Measure	Absorb BVS n=1220 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=636 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Dyspnea Severity	0.81 score on a scale Standard Deviation 1.24	0.88 score on a scale Standard Deviation 1.29

OTHER_PRE_SPECIFIED outcome

Timeframe: 12 months

Population: ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.

Dyspnea severity assessed using the Rose Dyspnea Scale (RDS). Rose Dyspnea Scale: * Scale range: 0 to 4 * Lower values represent better outcomes (higher scores indicate worse dyspnea) * No subscales

Outcome measures

Outcome measures
Measure	Absorb BVS n=1080 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=568 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Patient Reported Outcomes (PRO): Dyspnea Severity	0.94 score on a scale Standard Deviation 1.26	0.99 score on a scale Standard Deviation 1.30

OTHER_PRE_SPECIFIED outcome

Timeframe: 3-4 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TVMI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR).

Outcome measures

Outcome measures
Measure	Absorb BVS n=1202 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=610 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Landmark Analysis on TLF and Components	38 Participants	16 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 3-5 years

Population: ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1108 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=580 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Landmark Analysis on TLF and Components	60 Participants	38 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 3-4 years

Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab. Timing : Acute : 0 - 24 hours post stent implantation; Subacute : \>24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : \>1 year post stent implantation. Evidence: Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of * Any unexplained death within the first 30 days or * Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1180 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=607 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Landmark Analysis on Cumulative Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable) Definite	1 Participants	1 Participants
Landmark Analysis on Cumulative Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable) Probable	0 Participants	0 Participants
Landmark Analysis on Cumulative Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable) Definite/Probable	1 Participants	1 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 3-5 years

Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab. Timing : Acute : 0 - 24 hours post stent implantation; Subacute : \>24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : \>1 year post stent implantation. Evidence: Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of * Any unexplained death within the first 30 days or * Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.

Outcome measures

Outcome measures
Measure	Absorb BVS n=1059 Participants Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=556 Participants Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Landmark Analysis on Cumulative Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable) Definite/Probable	1 Participants	2 Participants
Landmark Analysis on Cumulative Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable) Definite	1 Participants	2 Participants
Landmark Analysis on Cumulative Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable) Probable	0 Participants	0 Participants

Adverse Events

Absorb BVS

Serious events: 801 serious events

Other events: 1174 other events

Deaths: 85 deaths

XIENCE

Serious events: 398 serious events

Other events: 601 other events

Deaths: 44 deaths

Serious adverse events

Serious adverse events
Measure	Absorb BVS n=1322 participants at risk Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=686 participants at risk Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Blood and lymphatic system disorders ANAEMIA	0.53% 7/1322 • 5 years	1.0% 7/686 • 5 years
Blood and lymphatic system disorders ANAEMIA OF CHRONIC DISEASE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Blood and lymphatic system disorders COAGULOPATHY	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Blood and lymphatic system disorders FEBRILE NEUTROPENIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders HAEMORRHAGIC ANAEMIA	0.15% 2/1322 • 5 years	0.44% 3/686 • 5 years
Blood and lymphatic system disorders HEPARIN-INDUCED THROMBOCYTOPENIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders IRON DEFICIENCY ANEMIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Blood and lymphatic system disorders LEUKOCYTOSIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Blood and lymphatic system disorders LYMPHADENOPATHY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders MICROCYTIC ANAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders NORMOCHROMIC NORMOCYTIC ANAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders THROMBOCYTOPENIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ACUTE CORONARY SYNDROME	0.45% 6/1322 • 5 years	0.73% 5/686 • 5 years
Cardiac disorders ACUTE LEFT VENTRICULAR FAILURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ACUTE MYOCARDIAL INFARCTION	3.7% 49/1322 • 5 years	3.1% 21/686 • 5 years
Cardiac disorders ANGINA PECTORIS	12.2% 161/1322 • 5 years	12.7% 87/686 • 5 years
Cardiac disorders ANGINA UNSTABLE	5.1% 68/1322 • 5 years	4.1% 28/686 • 5 years
Cardiac disorders AORTIC VALVE DISEASE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders AORTIC VALVE STENOSIS	0.45% 6/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders ARRHYTHMIA	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders ARTERIOSCLEROSIS CORONARY ARTERY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders ARTERIOSPASM CORONARY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders ATRIAL FIBRILLATION	3.9% 52/1322 • 5 years	3.1% 21/686 • 5 years
Cardiac disorders ATRIAL FLUTTER	0.45% 6/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders ATRIAL TACHYCARDIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ATRIOVENTRICULAR BLOCK	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders ATRIOVENTRICULAR BLOCK COMPLETE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ATRIOVENTRICULAR BLOCK SECOND DEGREE	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders BRADYCARDIA	0.68% 9/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders BUNDLE BRANCH BLOCK	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CARDIAC ARREST	0.76% 10/1322 • 5 years	0.87% 6/686 • 5 years
Cardiac disorders CARDIAC FAILURE	0.61% 8/1322 • 5 years	0.58% 4/686 • 5 years
Cardiac disorders CARDIAC FAILURE ACUTE	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CARDIAC FAILURE CHRONIC	0.15% 2/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders CARDIAC FAILURE CONGESTIVE	2.4% 32/1322 • 5 years	3.6% 25/686 • 5 years
Cardiac disorders CARDIAC TAMPONADE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CARDIAC VALVE DISEASE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CARDIO-RESPIRATORY ARREST	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CARDIOGENIC SHOCK	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders CARDIOMYOPATHY	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CARDIORENAL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CHRONIC LEFT VENTRICULAR FAILURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CONDUCTION DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CONGESTIVE CARDIOMYOPATHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CORONARY ARTERY DISEASE	2.9% 38/1322 • 5 years	3.5% 24/686 • 5 years
Cardiac disorders CORONARY ARTERY DISSECTION	1.7% 22/1322 • 5 years	1.7% 12/686 • 5 years
Cardiac disorders CORONARY ARTERY EMBOLISM	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders CORONARY ARTERY OCCLUSION	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders CORONARY ARTERY PERFORATION	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders CORONARY ARTERY STENOSIS	1.5% 20/1322 • 5 years	1.9% 13/686 • 5 years
Cardiac disorders CORONARY OSTIAL STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders DRESSLER'S SYNDROME	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders IN-STENT CORONARY ARTERY RESTENOSIS	0.30% 4/1322 • 5 years	0.73% 5/686 • 5 years
Cardiac disorders INTRACARDIAC THROMBUS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders ISCHAEMIC CARDIOMYOPATHY	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders LEFT VENTRICULAR DYSFUNCTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders MITRAL VALVE INCOMPETENCE	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders MYOCARDIAL INFARCTION	3.9% 52/1322 • 5 years	3.4% 23/686 • 5 years
Cardiac disorders MYOCARDIAL ISCHAEMIA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders PALPITATIONS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders PERICARDIAL EFFUSION	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders PERICARDITIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders PRINZMETAL ANGINA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders SICK SINUS SYNDROME	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders SINUS ARRHYTHMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders SINUS BRADYCARDIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders SUPRAVENTRICULAR TACHYCARDIA	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders TACHYCARDIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders TORSADE DE POINTES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders VENTRICULAR ARRHYTHMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders VENTRICULAR EXTRASYSTOLES	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders VENTRICULAR FIBRILLATION	0.38% 5/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders VENTRICULAR TACHYCARDIA	0.61% 8/1322 • 5 years	0.44% 3/686 • 5 years
Congenital, familial and genetic disorders CYSTIC LYMPHANGIOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Congenital, familial and genetic disorders PULMONARY ARTERIOVENOUS FISTULA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Ear and labyrinth disorders VERTIGO	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Eye disorders AMAUROSIS FUGAX	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders CATARACT	0.00% 0/1322 • 5 years	0.44% 3/686 • 5 years
Eye disorders CATARACT NUCLEAR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders DIPLOPIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders GLAUCOMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders MACULAR OEDEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders PAPILLOEDEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders POSTERIOR CAPSULE OPACIFICATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders RETINAL DETACHMENT	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Eye disorders RETINAL HAEMORRHAGE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Eye disorders VISION BLURRED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ABDOMINAL HERNIA	0.23% 3/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders ABDOMINAL HERNIA OBSTRUCTIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ABDOMINAL PAIN	0.23% 3/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders ABDOMINAL PAIN UPPER	0.15% 2/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders ABDOMINAL WALL HAEMATOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ALCOHOLIC PANCREATITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders COELIAC ARTERY STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders COLITIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders COLITIS ISCHAEMIC	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders CONSTIPATION	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders CROHN'S DISEASE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DENTAL CARIES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DIABETIC GASTROPARESIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DIARRHOEA	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders DIVERTICULUM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders DIVERTICULUM INTESTINAL HAEMORRHAGIC	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders DUODENAL ULCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DUODENAL ULCER HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DYSPHAGIA	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders ENTEROVESICAL FISTULA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders FAECALOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTRIC HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTRIC ULCER	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders GASTRIC ULCER HAEMORRHAGE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTRITIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTROINTESTINAL ANGIODYSPLASIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTROINTESTINAL HAEMORRHAGE	0.98% 13/1322 • 5 years	1.9% 13/686 • 5 years
Gastrointestinal disorders GASTROINTESTINAL ULCER HAEMORRHAGE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders GASTROOESOPHAGEAL REFLUX DISEASE	0.38% 5/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders HAEMATEMESIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders HAEMATOCHEZIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders HAEMORRHOIDAL HAEMORRHAGE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders HIATUS HERNIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders ILEUS	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders IMPAIRED GASTRIC EMPTYING	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders INGUINAL HERNIA	0.15% 2/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders INTESTINAL MASS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders INTESTINAL OBSTRUCTION	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders IRRITABLE BOWEL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders LARGE INTESTINE PERFORATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders LOWER GASTROINTESTINAL HAEMORRHAGE	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders MALLORY-WEISS SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders MELAENA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders MOUTH HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders OESOPHAGEAL ACHALASIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders OESOPHAGITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders PANCREATIC CYST	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders PANCREATITIS	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders PANCREATITIS ACUTE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders RECTAL HAEMORRHAGE	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders RETROPERITONEAL HAEMORRHAGE	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders SMALL INTESTINAL OBSTRUCTION	0.23% 3/1322 • 5 years	0.87% 6/686 • 5 years
Gastrointestinal disorders SMALL INTESTINAL PERFORATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders UMBILICAL HERNIA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders UMBILICAL HERNIA, OBSTRUCTIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders UPPER GASTROINTESTINAL HAEMORRHAGE	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
General disorders ABASIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders ADVERSE DRUG REACTION	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
General disorders ASTHENIA	0.38% 5/1322 • 5 years	0.00% 0/686 • 5 years
General disorders CARDIAC DEATH	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders CATHETER SITE HAEMATOMA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
General disorders CATHETER SITE HAEMORRHAGE	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
General disorders CATHETER SITE PAIN	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
General disorders CHEST DISCOMFORT	0.76% 10/1322 • 5 years	1.2% 8/686 • 5 years
General disorders CHEST PAIN	3.0% 40/1322 • 5 years	2.6% 18/686 • 5 years
General disorders DEATH	0.76% 10/1322 • 5 years	0.87% 6/686 • 5 years
General disorders DEVICE ELECTRICAL FINDING	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders DEVICE FAILURE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
General disorders DEVICE MALFUNCTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders DEVICE OCCLUSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders DROWNING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders DRUG INTOLERANCE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders DRUG WITHDRAWAL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders HERNIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders HERNIA OBSTRUCTIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders IMPAIRED HEALING	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders MEDICAL DEVICE SITE REACTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders MULTI-ORGAN FAILURE	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
General disorders NON-CARDIAC CHEST PAIN	6.4% 84/1322 • 5 years	7.4% 51/686 • 5 years
General disorders OEDEMA PERIPHERAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders PELVIC MASS	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
General disorders PYREXIA	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
General disorders SUDDEN CARDIAC DEATH	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders SURGICAL FAILURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders SYSTEMIC INFLAMMATORY RESPONSE SYNDROME	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
General disorders THROMBOSIS IN DEVICE	0.68% 9/1322 • 5 years	0.87% 6/686 • 5 years
Hepatobiliary disorders BILE DUCT STONE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders CHOLANGITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders CHOLECYSTITIS	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Hepatobiliary disorders CHOLECYSTITIS ACUTE	0.15% 2/1322 • 5 years	0.58% 4/686 • 5 years
Hepatobiliary disorders CHOLECYSTITIS CHRONIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders CHOLELITHIASIS	0.53% 7/1322 • 5 years	0.44% 3/686 • 5 years
Hepatobiliary disorders GALLBLADDER DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders HEPATIC LESION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Hepatobiliary disorders PORTAL VEIN THROMBOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Immune system disorders ALLERGY TO ARTHROPOD STING	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations ABDOMINAL ABSCESS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations ABSCESS NECK	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations APPENDICITIS	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations APPENDICITIS PERFORATED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ARTHRITIS BACTERIAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ARTHRITIS INFECTIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations BACTERAEMIA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations BACTERIAL INFECTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations BACTERIAL SEPSIS	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations BREAST CELLULITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations BRONCHITIS	0.76% 10/1322 • 5 years	0.87% 6/686 • 5 years
Infections and infestations BRONCHITIS VIRAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations CATHETER SITE ABSCESS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations CATHETER SITE CELLULITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations CATHETER SITE INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations CELLULITIS	0.83% 11/1322 • 5 years	1.6% 11/686 • 5 years
Infections and infestations CHOLECYSTITIS INFECTIVE	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations CLOSTRIDIAL INFECTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations CLOSTRIDIUM DIFFICILE COLITIS	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations CYSTITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations DIABETIC FOOT INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations DIVERTICULITIS	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations ENDOCARDITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ENTEROCOCCAL SEPSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations ESCHERICHIA BACTERAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations FUNGAL INFECTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations GANGRENE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations GASTROENTERITIS	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations GASTROENTERITIS VIRAL	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations GENITAL INFECTION FEMALE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations HERPES ZOSTER	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations HIV INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations IMPLANT SITE INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations INFECTED DERMAL CYST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations INFECTED SKIN ULCER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations INFLUENZA	0.23% 3/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations KIDNEY INFECTION	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations LOBAR PNEUMONIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations LOCALISED INFECTION	0.00% 0/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations LUNG ABSCESS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations MENINGITIS ASEPTIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations METAPNEUMOVIRUS INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations MYCOBACTERIUM ABSCESSUS INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ORAL FUNGAL INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ORCHITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations OSTEOMYELITIS	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
Infections and infestations PERITONITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations PERITONSILLAR ABSCESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA	1.9% 25/1322 • 5 years	2.8% 19/686 • 5 years
Infections and infestations PNEUMONIA ADENOVIRAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA BACTERIAL	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA NECROTISING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA PRIMARY ATYPICAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA STAPHYLOCOCCAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations POST PROCEDURAL CELLULITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations POST PROCEDURAL INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations POST PROCEDURAL PNEUMONIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations POSTOPERATIVE WOUND INFECTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations RESPIRATORY SYNCYTIAL VIRUS INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations SEPSIS	1.1% 14/1322 • 5 years	1.5% 10/686 • 5 years
Infections and infestations SEPSIS SYNDROME	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations SEPTIC ENCEPHALOPATHY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations SEPTIC SHOCK	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations SPINAL CORD INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations STAPHYLOCOCCAL BACTERAEMIA	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations STAPHYLOCOCCAL INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations URINARY TRACT INFECTION	0.68% 9/1322 • 5 years	1.0% 7/686 • 5 years
Infections and infestations URINARY TRACT INFECTION BACTERIAL	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations UROSEPSIS	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
Infections and infestations VIRAL INFECTION	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations VIRAL LABYRINTHITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations WOUND INFECTION	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations WOUND INFECTION BACTERIAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations WOUND INFECTION STAPHYLOCOCCAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ACETABULUM FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ALCOHOL POISONING	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications ANAEMIA POSTOPERATIVE	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications ANKLE FRACTURE	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Injury, poisoning and procedural complications BURNS THIRD DEGREE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CARDIAC PROCEDURE COMPLICATION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CEREBRAL HAEMORRHAGE TRAUMATIC	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications CLAVICLE FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications COLON INJURY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications CONCUSSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications CONTRAST MEDIA ALLERGY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CONTUSION	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications CORONARY ARTERY RESTENOSIS	3.9% 51/1322 • 5 years	2.2% 15/686 • 5 years
Injury, poisoning and procedural complications CRANIOCEREBRAL INJURY	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications CYSTITIS RADIATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications DEEP VEIN THROMBOSIS POSTOPERATIVE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications EXPOSURE TO TOXIC AGENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications FALL	0.68% 9/1322 • 5 years	1.0% 7/686 • 5 years
Injury, poisoning and procedural complications FEMORAL NECK FRACTURE	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications FEMUR FRACTURE	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications FOOT FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications GASTROINTESTINAL ANASTOMOTIC LEAK	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications HAND FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications HEAD INJURY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications HIP FRACTURE	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications HUMERUS FRACTURE	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications ILIOTIBIAL BAND SYNDROME	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications IN-STENT ARTERIAL RESTENOSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications IN-STENT CORONARY ARTERY RESTENOSIS	0.53% 7/1322 • 5 years	0.73% 5/686 • 5 years
Injury, poisoning and procedural complications INCISIONAL HERNIA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications INJURY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications JOINT DISLOCATION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications LACERATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications LIGAMENT RUPTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications LIMB INJURY	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications LIMB TRAUMATIC AMPUTATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications MENISCUS LESION	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications MULTIPLE FRACTURES	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications MULTIPLE INJURIES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications MUSCLE RUPTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications PELVIC FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PLAQUE SHIFT	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Injury, poisoning and procedural complications POST CONCUSSION SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL HAEMATOMA	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL HAEMORRHAGE	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL MYOCARDIAL INFARCTION	0.53% 7/1322 • 5 years	0.73% 5/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL STROKE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications POST-TRAUMATIC PAIN	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications POSTOPERATIVE ADHESION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL COMPLICATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL DIZZINESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL HEADACHE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL HYPOTENSION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL VOMITING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications RADIUS FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications RESPIRATORY FUME INHALATION DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications RIB FRACTURE	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications ROAD TRAFFIC ACCIDENT	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SEROMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SKULL FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SNAKE BITE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SPINAL COMPRESSION FRACTURE	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications SPINAL FRACTURE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SPLENIC RUPTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications STERNAL FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications SUBDURAL HAEMATOMA	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
Injury, poisoning and procedural complications TENDON INJURY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications TENDON RUPTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications THERMAL BURN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications THORACIC VERTEBRAL FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications TIBIA FRACTURE	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications TRAUMATIC HAEMATOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications TRAUMATIC HAEMORRHAGE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ULNA FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications UPPER LIMB FRACTURE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications URINARY RETENTION POSTOPERATIVE	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications VASCULAR GRAFT OCCLUSION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications VASCULAR PSEUDOANEURYSM	0.53% 7/1322 • 5 years	0.44% 3/686 • 5 years
Injury, poisoning and procedural complications WOUND	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications WOUND EVISCERATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications WOUND HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications WRIST FRACTURE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BIOPSY LUNG	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD CREATINE INCREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD CREATINE PHOSPHOKINASE MB INCREASED	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD CREATININE INCREASED	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD PRESSURE INCREASED	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD PRESSURE SYSTOLIC INCREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations CARDIAC ENZYMES INCREASED	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Investigations CARDIAC STRESS TEST ABNORMAL	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Investigations COMPUTERISED TOMOGRAM ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations COMPUTERISED TOMOGRAM THORAX ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations EJECTION FRACTION DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations ELECTROCARDIOGRAM ST SEGMENT ELEVATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations HAEMOGLOBIN DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations HEART RATE INCREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations OXYGEN CONSUMPTION INCREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations TROPONIN INCREASED	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Investigations WHITE BLOOD CELL COUNT INCREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders DEHYDRATION	0.53% 7/1322 • 5 years	0.73% 5/686 • 5 years
Metabolism and nutrition disorders DIABETES MELLITUS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders DIABETIC KETOACIDOSIS	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders FAILURE TO THRIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders FLUID OVERLOAD	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders HYPERGLYCAEMIA	0.45% 6/1322 • 5 years	0.29% 2/686 • 5 years
Metabolism and nutrition disorders HYPERKALAEMIA	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Metabolism and nutrition disorders HYPOGLYCAEMIA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders HYPOKALAEMIA	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders HYPOMAGNESAEMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders HYPONATRAEMIA	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Metabolism and nutrition disorders HYPOVOLAEMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders LACTIC ACIDOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders METABOLIC ACIDOSIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders OBESITY	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
Musculoskeletal and connective tissue disorders ARTHRALGIA	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Musculoskeletal and connective tissue disorders ARTHRITIS	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders BACK PAIN	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
Musculoskeletal and connective tissue disorders BURSITIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders CHONDROCALCINOSIS PYROPHOSPHATE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders COSTOCHONDRITIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders DUPUYTREN'S CONTRACTURE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders EXOSTOSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders FLANK PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders FRACTURE NONUNION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders INTERVERTEBRAL DISC PROTRUSION	0.68% 9/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders JOINT EFFUSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders LUMBAR SPINAL STENOSIS	0.53% 7/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULAR WEAKNESS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL CHEST PAIN	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL PAIN	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Musculoskeletal and connective tissue disorders NECK PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders OSTEOARTHRITIS	2.0% 26/1322 • 5 years	2.0% 14/686 • 5 years
Musculoskeletal and connective tissue disorders OSTEOPENIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders OSTEOPOROSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders PAIN IN JAW	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders RHABDOMYOLYSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders RHEUMATOID ARTHRITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders ROTATOR CUFF SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders SACROILIITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders SPINAL OSTEOARTHRITIS	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders SPONDYLITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders SPONDYLOLISTHESIS	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders TENDINOUS CONTRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders VERTEBRAL FORAMINAL STENOSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ACUTE MYELOID LEUKAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ACUTE MYELOID LEUKAEMIA RECURRENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ADENOCARCINOMA	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ADENOCARCINOMA PANCREAS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) B-CELL LYMPHOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) B-CELL LYMPHOMA STAGE IV	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BASAL CELL CARCINOMA	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BENIGN OVARIAN TUMOUR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BILE DUCT CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER CANCER	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER CANCER RECURRENT	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER CANCER STAGE IV	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER NEOPLASM	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BRAIN NEOPLASM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BREAST CANCER	0.38% 5/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BREAST CANCER STAGE III	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) CERVIX CARCINOMA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) CHRONIC LYMPHOCYTIC LEUKAEMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) COLON ADENOMA	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) COLON CANCER	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) DIFFUSE LARGE B-CELL LYMPHOMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) GASTRIC CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) GLIOBLASTOMA	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HEAD AND NECK CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HEAD AND NECK CANCER METASTATIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HEPATIC CANCER METASTATIC	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HEPATIC NEOPLASM MALIGNANT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HYPOPHARYNGEAL CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LEUKAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LEUKAEMIA RECURRENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LIP AND/OR ORAL CAVITY CANCER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG ADENOCARCINOMA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG CANCER METASTATIC	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG NEOPLASM	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG NEOPLASM MALIGNANT	0.45% 6/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG SQUAMOUS CELL CARCINOMA STAGE III	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LYMPHOMA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MALIGNANT MELANOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MENINGIOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO LIVER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO LUNG	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO LYMPH NODES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO SPINE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTATIC MALIGNANT MELANOMA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTATIC NEOPLASM	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MULTIPLE MYELOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NEOPLASM MALIGNANT	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NON-HODGKIN'S LYMPHOMA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NON-SMALL CELL LUNG CANCER	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OESOPHAGEAL CARCINOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ORAL NEOPLASM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OROPHARYNGEAL CANCER STAGE UNSPECIFIED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OVARIAN CANCER METASTATIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OVARIAN EPITHELIAL CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PANCREATIC CARCINOMA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PERICARDIAL EFFUSION MALIGNANT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PROSTATE CANCER	0.83% 11/1322 • 5 years	0.44% 3/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RECTAL CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL CANCER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL CELL CARCINOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL NEOPLASM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SINONASAL PAPILLOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SKIN CANCER	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SMALL CELL LUNG CANCER LIMITED STAGE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SMALL CELL LUNG CANCER STAGE UNSPECIFIED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SQUAMOUS CELL CARCINOMA	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SQUAMOUS CELL CARCINOMA OF SKIN	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) TRANSITIONAL CELL CARCINOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) URETERIC CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) UTERINE CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) VULVAL CANCER STAGE 0	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders ALTERED STATE OF CONSCIOUSNESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders APHASIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders ARACHNOIDITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders AUTONOMIC NERVOUS SYSTEM IMBALANCE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CAROTID ARTERY DISEASE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CAROTID ARTERY STENOSIS	0.83% 11/1322 • 5 years	1.0% 7/686 • 5 years
Nervous system disorders CARPAL TUNNEL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CENTRAL NERVOUS SYSTEM LESION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CEREBELLAR INFARCTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CEREBRAL HAEMORRHAGE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders CEREBRAL INFARCTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders CEREBROVASCULAR ACCIDENT	1.4% 19/1322 • 5 years	2.2% 15/686 • 5 years
Nervous system disorders CEREBROVASCULAR DISORDER	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders CERVICOBRACHIAL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders COMPLICATED MIGRAINE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CONVULSION	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders DIABETIC NEUROPATHY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders DIZZINESS	0.45% 6/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders DYSARTHRIA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders EMBOLIC STROKE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders ENCEPHALOPATHY	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders GUILLAIN-BARRE SYNDROME	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HAEMORRHAGE INTRACRANIAL	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders HAEMORRHAGIC STROKE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HEADACHE	0.15% 2/1322 • 5 years	0.44% 3/686 • 5 years
Nervous system disorders HEMIPARESIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders HEMIPLEGIC MIGRAINE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HEPATIC ENCEPHALOPATHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HYPOAESTHESIA	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Nervous system disorders HYPOXIC-ISCHAEMIC ENCEPHALOPATHY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders ISCHAEMIC STROKE	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Nervous system disorders LATERAL MEDULLARY SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders LOSS OF CONSCIOUSNESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders LUMBAR RADICULOPATHY	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders METABOLIC ENCEPHALOPATHY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders MIGRAINE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders MYELOMALACIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders NEUROLOGICAL SYMPTOM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders NYSTAGMUS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders PARAESTHESIA	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders POLYNEUROPATHY ALCOHOLIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders POST-TRAUMATIC HEADACHE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders PRESYNCOPE	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders RADICULITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders RADICULITIS CERVICAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders SPONDYLITIC MYELOPATHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders SUBARACHNOID HAEMORRHAGE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders SUBDURAL HYGROMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders SYNCOPE	1.8% 24/1322 • 5 years	1.9% 13/686 • 5 years
Nervous system disorders THALAMIC INFARCTION	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders THROMBOTIC STROKE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders TRANSIENT ISCHAEMIC ATTACK	0.83% 11/1322 • 5 years	0.87% 6/686 • 5 years
Nervous system disorders UNRESPONSIVE TO STIMULI	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders URAEMIC ENCEPHALOPATHY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders VERTEBRAL ARTERY OCCLUSION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders VITH NERVE PARALYSIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders ACUTE STRESS DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders ADJUSTMENT DISORDER WITH MIXED DISTURBANCE OF EMOTION AND CONDUCT	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders ALCOHOL ABUSE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders ALCOHOL WITHDRAWAL SYNDROME	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders ANXIETY	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders BIPOLAR DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders COMPLETED SUICIDE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders CONFUSIONAL STATE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders DELIRIUM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders DELIRIUM TREMENS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders DEPRESSION SUICIDAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders HALLUCINATION, VISUAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders INTENTIONAL SELF-INJURY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders MAJOR DEPRESSION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders MENTAL STATUS CHANGES	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Psychiatric disorders PANIC ATTACK	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders SUICIDAL IDEATION	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Renal and urinary disorders CALCULUS URETERIC	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Renal and urinary disorders HAEMATURIA	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Renal and urinary disorders HYDRONEPHROSIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Renal and urinary disorders NEPHROLITHIASIS	0.53% 7/1322 • 5 years	1.0% 7/686 • 5 years
Renal and urinary disorders RENAL ARTERY STENOSIS	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Renal and urinary disorders RENAL DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders RENAL FAILURE	0.38% 5/1322 • 5 years	0.58% 4/686 • 5 years
Renal and urinary disorders RENAL FAILURE ACUTE	0.91% 12/1322 • 5 years	1.7% 12/686 • 5 years
Renal and urinary disorders RENAL FAILURE CHRONIC	0.15% 2/1322 • 5 years	0.44% 3/686 • 5 years
Renal and urinary disorders RENAL IMPAIRMENT	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Renal and urinary disorders RENAL TUBULAR NECROSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders STRESS URINARY INCONTINENCE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders URINARY RETENTION	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Reproductive system and breast disorders BENIGN PROSTATIC HYPERPLASIA	0.23% 3/1322 • 5 years	0.44% 3/686 • 5 years
Reproductive system and breast disorders FALLOPIAN TUBE CYST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders PELVIC HAEMATOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders UTERINE POLYP	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders VAGINAL HAEMORRHAGE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Reproductive system and breast disorders VULVA CYST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders ACUTE PULMONARY OEDEMA	0.00% 0/1322 • 5 years	0.58% 4/686 • 5 years
Respiratory, thoracic and mediastinal disorders ACUTE RESPIRATORY FAILURE	1.2% 16/1322 • 5 years	1.0% 7/686 • 5 years
Respiratory, thoracic and mediastinal disorders ASPIRATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders ASTHMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders CHRONIC OBSTRUCTIVE PULMONARY DISEASE	2.1% 28/1322 • 5 years	1.5% 10/686 • 5 years
Respiratory, thoracic and mediastinal disorders DYSPHONIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders DYSPNOEA	2.5% 33/1322 • 5 years	1.9% 13/686 • 5 years
Respiratory, thoracic and mediastinal disorders DYSPNOEA EXERTIONAL	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Respiratory, thoracic and mediastinal disorders EPISTAXIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders HAEMOPTYSIS	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Respiratory, thoracic and mediastinal disorders HYPERVENTILATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders HYPOXIA	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Respiratory, thoracic and mediastinal disorders INTERSTITIAL LUNG DISEASE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders MEDIASTINAL MASS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders NASAL POLYPS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders NON-CARDIOGENIC PULMONARY OEDEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders ORGANISING PNEUMONIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders PLEURAL EFFUSION	0.30% 4/1322 • 5 years	0.44% 3/686 • 5 years
Respiratory, thoracic and mediastinal disorders PLEURITIC PAIN	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders PNEUMONIA ASPIRATION	0.00% 0/1322 • 5 years	0.58% 4/686 • 5 years
Respiratory, thoracic and mediastinal disorders PNEUMONITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders PNEUMOTHORAX	0.15% 2/1322 • 5 years	0.73% 5/686 • 5 years
Respiratory, thoracic and mediastinal disorders PULMONARY EMBOLISM	0.68% 9/1322 • 5 years	1.0% 7/686 • 5 years
Respiratory, thoracic and mediastinal disorders PULMONARY OEDEMA	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders RESPIRATORY ARREST	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders RESPIRATORY FAILURE	0.98% 13/1322 • 5 years	1.2% 8/686 • 5 years
Respiratory, thoracic and mediastinal disorders TRACHEAL STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders DIABETIC FOOT	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders RASH	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders SKIN ULCER	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures AORTIC ANEURYSM REPAIR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures CHOLECYSTECTOMY	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures COLOSTOMY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures CORONARY ARTERY BYPASS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures HIP ARTHROPLASTY	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures INGUINAL HERNIA REPAIR	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures KNEE ARTHROPLASTY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures LEG AMPUTATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures MEDICAL DEVICE REMOVAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures NEPHRECTOMY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures SPINAL FUSION SURGERY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures TENDON OPERATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures TRANSURETHRAL PROSTATECTOMY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders ACCELERATED HYPERTENSION	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders AORTIC ANEURYSM	0.45% 6/1322 • 5 years	0.29% 2/686 • 5 years
Vascular disorders AORTIC DISSECTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders AORTIC INTRAMURAL HAEMATOMA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders AORTIC STENOSIS	0.30% 4/1322 • 5 years	0.73% 5/686 • 5 years
Vascular disorders ARTERIAL SPASM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders ARTERIOSCLEROSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders BLOOD PRESSURE INADEQUATELY CONTROLLED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders CIRCULATORY COLLAPSE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders DEEP VEIN THROMBOSIS	0.83% 11/1322 • 5 years	0.58% 4/686 • 5 years
Vascular disorders FEMORAL ARTERIAL STENOSIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders HAEMATOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders HYPERTENSION	0.61% 8/1322 • 5 years	0.29% 2/686 • 5 years
Vascular disorders HYPERTENSIVE CRISIS	0.23% 3/1322 • 5 years	0.73% 5/686 • 5 years
Vascular disorders HYPOTENSION	0.38% 5/1322 • 5 years	0.58% 4/686 • 5 years
Vascular disorders ILIAC ARTERY STENOSIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders INTERMITTENT CLAUDICATION	0.61% 8/1322 • 5 years	1.0% 7/686 • 5 years
Vascular disorders MALIGNANT HYPERTENSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders ORTHOSTATIC HYPOTENSION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	0.23% 3/1322 • 5 years	1.2% 8/686 • 5 years
Vascular disorders PERIPHERAL ISCHAEMIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders PERIPHERAL VASCULAR DISORDER	0.53% 7/1322 • 5 years	0.87% 6/686 • 5 years
Vascular disorders SUBCLAVIAN ARTERY OCCLUSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders SUBCLAVIAN ARTERY STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders SUBCLAVIAN STEAL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders THROMBOSIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders VASOSPAM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders VENOUS INSUFFICIENCY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years

Other adverse events

Other adverse events
Measure	Absorb BVS n=1322 participants at risk Subjects receiving Absorb BVS Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm * Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter. * The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study. Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.	XIENCE n=686 participants at risk Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only). * Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm * Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition * For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MENINGIOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO LIVER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO LUNG	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO LYMPH NODES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTASES TO SPINE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTATIC MALIGNANT MELANOMA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) METASTATIC NEOPLASM	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MULTIPLE MYELOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NEOPLASM MALIGNANT	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NEURILEMMOMA MALIGNANT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NON-HODGKIN'S LYMPHOMA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) NON-SMALL CELL LUNG CANCER	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Blood and lymphatic system disorders ANAEMIA	1.6% 21/1322 • 5 years	2.3% 16/686 • 5 years
Blood and lymphatic system disorders ANAEMIA OF CHRONIC DISEASE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Blood and lymphatic system disorders COAGULOPATHY	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Blood and lymphatic system disorders FEBRILE NEUTROPENIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders HAEMORRHAGIC ANAEMIA	0.15% 2/1322 • 5 years	0.58% 4/686 • 5 years
Blood and lymphatic system disorders HAEMORRHAGIC DIATHESIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Blood and lymphatic system disorders HEPARIN-INDUCED THROMBOCYTOPENIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders IRON DEFICIENCY ANAEMIA	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Blood and lymphatic system disorders LEUKOCYTOSIS	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Blood and lymphatic system disorders LYMPHADENITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders LYMPHADENOPATHY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders MICROCYTIC ANAEMIA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders NORMOCHROMIC NORMOCYTIC ANAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders SPLENIC INFARCTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Blood and lymphatic system disorders THROMBOCYTOPENIA	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders ACUTE CORONARY SYNDROME	0.45% 6/1322 • 5 years	0.73% 5/686 • 5 years
Cardiac disorders ACUTE LEFT VENTRICULAR FAILURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ACUTE MYOCARDIAL INFARCTION	3.7% 49/1322 • 5 years	3.2% 22/686 • 5 years
Cardiac disorders ANGINA PECTORIS	28.8% 381/1322 • 5 years	29.4% 202/686 • 5 years
Cardiac disorders ANGINA UNSTABLE	5.8% 77/1322 • 5 years	4.2% 29/686 • 5 years
Cardiac disorders AORTIC VALVE DISEASE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders AORTIC VALVE INCOMPETENCE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders AORTIC VALVE STENOSIS	0.61% 8/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders ARRHYTHMIA	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders ARTERIOSCLEROSIS CORONARY ARTERY	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders ARTERIOSPASM CORONARY	0.30% 4/1322 • 5 years	0.58% 4/686 • 5 years
Cardiac disorders ATRIAL FIBRILLATION	7.2% 95/1322 • 5 years	6.1% 42/686 • 5 years
Cardiac disorders ATRIAL FLUTTER	0.83% 11/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders ATRIAL HYPERTROPHY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ATRIAL TACHYCARDIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ATRIAL THROMBOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders ATRIOVENTRICULAR BLOCK	0.45% 6/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders ATRIOVENTRICULAR BLOCK COMPLETE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ATRIOVENTRICULAR BLOCK SECOND DEGREE	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders BRADYCARDIA	2.3% 31/1322 • 5 years	1.9% 13/686 • 5 years
Cardiac disorders BUNDLE BRANCH BLOCK	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders BUNDLE BRANCH BLOCK LEFT	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders BUNDLE BRANCH BLOCK RIGHT	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CARDIAC ARREST	0.76% 10/1322 • 5 years	0.87% 6/686 • 5 years
Cardiac disorders CARDIAC FAILURE	0.61% 8/1322 • 5 years	0.58% 4/686 • 5 years
Cardiac disorders CARDIAC FAILURE ACUTE	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CARDIAC FAILURE CHRONIC	0.15% 2/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders CARDIAC FAILURE CONGESTIVE	3.0% 39/1322 • 5 years	4.4% 30/686 • 5 years
Cardiac disorders CARDIAC FLUTTER	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CARDIAC TAMPONADE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CARDIAC VALVE DISEASE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CARDIO-RESPIRATORY ARREST	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CARDIOGENIC SHOCK	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders CARDIOMEGALY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CARDIOMYOPATHY	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders CARDIORENAL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CHRONIC LEFT VENTRICULAR FAILURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CONDUCTION DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CONGESTIVE CARDIOMYOPATHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CORONARY ARTERY DISEASE	3.3% 44/1322 • 5 years	4.1% 28/686 • 5 years
Cardiac disorders CORONARY ARTERY DISSECTION	6.4% 85/1322 • 5 years	8.2% 56/686 • 5 years
Cardiac disorders CORONARY ARTERY EMBOLISM	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
Cardiac disorders CORONARY ARTERY OCCLUSION	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders CORONARY ARTERY PERFORATION	0.53% 7/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders CORONARY ARTERY STENOSIS	1.7% 23/1322 • 5 years	2.0% 14/686 • 5 years
Cardiac disorders CORONARY NO-REFLOW PHENOMENON	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders CORONARY OSTIAL STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders CYANOSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders DIASTOLIC DYSFUNCTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders DRESSLER'S SYNDROME	0.00% 0/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders EXTRASYSTOLES	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders HEART VALVE INCOMPETENCE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders HYPERTROPHIC CARDIOMYOPATHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders IN-STENT CORONARY ARTERY RESTENOSIS	0.30% 4/1322 • 5 years	0.73% 5/686 • 5 years
Cardiac disorders INTRACARDIAC THROMBUS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders ISCHAEMIC CARDIOMYOPATHY	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Cardiac disorders LEFT VENTRICULAR DYSFUNCTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders LEFT VENTRICULAR HYPERTROPHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders MITRAL VALVE INCOMPETENCE	0.61% 8/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders MYOCARDIAL INFARCTION	4.1% 54/1322 • 5 years	3.5% 24/686 • 5 years
Cardiac disorders MYOCARDIAL ISCHAEMIA	0.45% 6/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders NODAL ARRHYTHMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders NODAL RHYTHM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders PALPITATIONS	2.4% 32/1322 • 5 years	2.5% 17/686 • 5 years
Cardiac disorders PERICARDIAL EFFUSION	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders PERICARDITIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders PRINZMETAL ANGINA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders SICK SINUS SYNDROME	0.45% 6/1322 • 5 years	0.58% 4/686 • 5 years
Cardiac disorders SINUS ARREST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders SINUS ARRHYTHMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders SINUS BRADYCARDIA	0.23% 3/1322 • 5 years	0.44% 3/686 • 5 years
Cardiac disorders SINUS TACHYCARDIA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders SUPRAVENTRICULAR EXTRASYSTOLES	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders SUPRAVENTRICULAR TACHYCARDIA	0.91% 12/1322 • 5 years	0.73% 5/686 • 5 years
Cardiac disorders TACHYCARDIA	0.91% 12/1322 • 5 years	0.87% 6/686 • 5 years
Cardiac disorders TORSADE DE POINTES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders TRICUSPID VALVE INCOMPETENCE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders VENTRICULAR ARRHYTHMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Cardiac disorders VENTRICULAR EXTRASYSTOLES	0.45% 6/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders VENTRICULAR FIBRILLATION	0.45% 6/1322 • 5 years	0.00% 0/686 • 5 years
Cardiac disorders VENTRICULAR TACHYCARDIA	1.1% 14/1322 • 5 years	0.87% 6/686 • 5 years
Congenital, familial and genetic disorders ARTERIOVENOUS MALFORMATION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Congenital, familial and genetic disorders CYSTIC LYMPHANGIOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Congenital, familial and genetic disorders MYOTONIC DYSTROPHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Congenital, familial and genetic disorders PULMONARY ARTERIOVENOUS FISTULA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Ear and labyrinth disorders DEAFNESS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Ear and labyrinth disorders EAR PAIN	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Ear and labyrinth disorders EUSTACHIAN TUBE OBSTRUCTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Ear and labyrinth disorders MIXED DEAFNESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Ear and labyrinth disorders TINNITUS	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Ear and labyrinth disorders TYMPANIC MEMBRANE PERFORATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Ear and labyrinth disorders VERTIGO	0.98% 13/1322 • 5 years	1.0% 7/686 • 5 years
Endocrine disorders ADRENAL MASS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Endocrine disorders GOITRE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Endocrine disorders HYPERTHYROIDISM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Endocrine disorders HYPOGONADISM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Endocrine disorders HYPOTHYROIDISM	0.45% 6/1322 • 5 years	0.15% 1/686 • 5 years
Endocrine disorders THYROID CYST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders AGE-RELATED MACULAR DEGENERATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders AMAUROSIS FUGAX	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders CATARACT	0.53% 7/1322 • 5 years	1.2% 8/686 • 5 years
Eye disorders CATARACT NUCLEAR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders CONJUNCTIVAL HAEMORRHAGE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders CONJUNCTIVITIS	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Eye disorders DIABETIC RETINOPATHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders DIPLOPIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders EYE PRURITUS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders EYE SWELLING	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Eye disorders GAZE PALSY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders GLAUCOMA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders MACULAR FIBROSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders MACULAR OEDEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders PAPILLOEDEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders POSTERIOR CAPSULE OPACIFICATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders RETINAL DETACHMENT	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Eye disorders RETINAL HAEMORRHAGE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Eye disorders SCLERAL DISCOLOURATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders SCLERAL HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Eye disorders VISION BLURRED	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Eye disorders VISUAL IMPAIRMENT	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ABDOMINAL DISCOMFORT	0.38% 5/1322 • 5 years	0.58% 4/686 • 5 years
Gastrointestinal disorders ABDOMINAL DISTENSION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders ABDOMINAL HERNIA	0.23% 3/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders ABDOMINAL HERNIA OBSTRUCTIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ABDOMINAL MASS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders ABDOMINAL PAIN	0.98% 13/1322 • 5 years	1.9% 13/686 • 5 years
Gastrointestinal disorders ABDOMINAL PAIN LOWER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ABDOMINAL PAIN UPPER	0.61% 8/1322 • 5 years	1.0% 7/686 • 5 years
Gastrointestinal disorders ABDOMINAL WALL HAEMATOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ALCOHOLIC PANCREATITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders BARRETT'S OESOPHAGUS	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders COELIAC ARTERY STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders COELIAC DISEASE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders COLITIS	0.30% 4/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders COLITIS ISCHAEMIC	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders COLONIC POLYP	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders CONSTIPATION	0.83% 11/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders CROHN'S DISEASE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders DENTAL CARIES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DIABETIC GASTROPARESIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DIARRHOEA	1.4% 18/1322 • 5 years	1.0% 7/686 • 5 years
Gastrointestinal disorders DIVERTICULUM	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders DIVERTICULUM INTESTINAL	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders DIVERTICULUM INTESTINAL HAEMORRHAGIC	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders DRY MOUTH	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DUODENAL ULCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DUODENAL ULCER HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DUODENITIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders DYSPEPSIA	1.1% 15/1322 • 5 years	0.58% 4/686 • 5 years
Gastrointestinal disorders DYSPHAGIA	0.76% 10/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders ENTEROVESICAL FISTULA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders EROSIVE OESOPHAGITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ERUCTATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders FAECAL INCONTINENCE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders FAECALOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders FAECES DISCOLOURED	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders FLATULENCE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders FOOD POISONING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders FUNCTIONAL GASTROINTESTINAL DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTRIC HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTRIC ULCER	0.15% 2/1322 • 5 years	0.58% 4/686 • 5 years
Gastrointestinal disorders GASTRIC ULCER HAEMORRHAGE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTRITIS	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders GASTRITIS EROSIVE	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTROINTESTINAL ANGIODYSPLASIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTROINTESTINAL DISORDER	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders GASTROINTESTINAL HAEMORRHAGE	1.2% 16/1322 • 5 years	2.2% 15/686 • 5 years
Gastrointestinal disorders GASTROINTESTINAL PAIN	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders GASTROINTESTINAL ULCER HAEMORRHAGE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders GASTROOESOPHAGEAL REFLUX DISEASE	1.7% 23/1322 • 5 years	1.2% 8/686 • 5 years
Gastrointestinal disorders HAEMATEMESIS	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders HAEMATOCHEZIA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders HAEMORRHOIDAL HAEMORRHAGE	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders HAEMORRHOIDS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders HIATUS HERNIA	0.68% 9/1322 • 5 years	0.58% 4/686 • 5 years
Gastrointestinal disorders HYPOAESTHESIA ORAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders ILEUS	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders IMPAIRED GASTRIC EMPTYING	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders INFREQUENT BOWEL MOVEMENTS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders INGUINAL HERNIA	0.30% 4/1322 • 5 years	0.87% 6/686 • 5 years
Gastrointestinal disorders INTESTINAL MASS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders INTESTINAL OBSTRUCTION	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders IRRITABLE BOWEL SYNDROME	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders LARGE INTESTINE PERFORATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders LOWER GASTROINTESTINAL HAEMORRHAGE	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders MALLORY-WEISS SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders MELAENA	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders MOUTH HAEMORRHAGE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders MOUTH ULCERATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders NAUSEA	1.4% 19/1322 • 5 years	1.9% 13/686 • 5 years
Gastrointestinal disorders OESOPHAGEAL ACHALASIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders OESOPHAGEAL FOOD IMPACTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders OESOPHAGEAL PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders OESOPHAGEAL SPASM	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders OESOPHAGEAL ULCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders OESOPHAGITIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders PANCREATIC CYST	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders PANCREATITIS	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Gastrointestinal disorders PANCREATITIS ACUTE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders PANCREATITIS CHRONIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders PEPTIC ULCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders PROCTALGIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders RECTAL HAEMORRHAGE	0.61% 8/1322 • 5 years	1.2% 8/686 • 5 years
Gastrointestinal disorders RECTAL PROLAPSE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders RETROPERITONEAL HAEMATOMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders RETROPERITONEAL HAEMORRHAGE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders SMALL INTESTINAL OBSTRUCTION	0.23% 3/1322 • 5 years	0.87% 6/686 • 5 years
Gastrointestinal disorders SMALL INTESTINAL PERFORATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders STOMATITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders TONGUE CYST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders TONGUE HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders TOOTH SOCKET HAEMORRHAGE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Gastrointestinal disorders UMBILICAL HERNIA	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Gastrointestinal disorders UMBILICAL HERNIA, OBSTRUCTIVE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Gastrointestinal disorders UPPER GASTROINTESTINAL HAEMORRHAGE	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
Gastrointestinal disorders VOMITING	0.98% 13/1322 • 5 years	1.5% 10/686 • 5 years
General disorders ABASIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders ADVERSE DRUG REACTION	5.6% 74/1322 • 5 years	6.1% 42/686 • 5 years
General disorders ASTHENIA	0.91% 12/1322 • 5 years	0.58% 4/686 • 5 years
General disorders BREAST COMPLICATION ASSOCIATED WITH DEVICE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders CARDIAC DEATH	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders CATHETER SITE HAEMATOMA	2.3% 30/1322 • 5 years	2.0% 14/686 • 5 years
General disorders CATHETER SITE HAEMORRHAGE	1.7% 22/1322 • 5 years	2.0% 14/686 • 5 years
General disorders CATHETER SITE PAIN	2.2% 29/1322 • 5 years	2.2% 15/686 • 5 years
General disorders CATHETER SITE RASH	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders CATHETER SITE RELATED REACTION	0.68% 9/1322 • 5 years	0.58% 4/686 • 5 years
General disorders CATHETER SITE SWELLING	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
General disorders CHEST DISCOMFORT	6.6% 87/1322 • 5 years	5.0% 34/686 • 5 years
General disorders CHEST PAIN	6.0% 79/1322 • 5 years	7.1% 49/686 • 5 years
General disorders CHILLS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders CYST	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
General disorders DEATH	0.76% 10/1322 • 5 years	0.87% 6/686 • 5 years
General disorders DEVICE ELECTRICAL FINDING	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders DEVICE FAILURE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
General disorders DEVICE MALFUNCTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders DEVICE OCCLUSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders DISCOMFORT	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
General disorders DROWNING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders DRUG INTOLERANCE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
General disorders DRUG WITHDRAWAL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders FACE OEDEMA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders FATIGUE	3.8% 50/1322 • 5 years	2.9% 20/686 • 5 years
General disorders FEELING COLD	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders GAIT DISTURBANCE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
General disorders GENERALISED OEDEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders HERNIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders HERNIA OBSTRUCTIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders HERNIA PAIN	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders IMPAIRED HEALING	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
General disorders IMPLANT SITE HAEMORRHAGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders IMPLANT SITE PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders INFLUENZA LIKE ILLNESS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
General disorders LOCAL SWELLING	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
General disorders MALAISE	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
General disorders MASS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
General disorders MEDICAL DEVICE SITE REACTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders MULTI-ORGAN FAILURE	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
General disorders NON-CARDIAC CHEST PAIN	20.5% 271/1322 • 5 years	17.8% 122/686 • 5 years
General disorders OEDEMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
General disorders OEDEMA PERIPHERAL	1.9% 25/1322 • 5 years	1.5% 10/686 • 5 years
General disorders PAIN	0.68% 9/1322 • 5 years	0.87% 6/686 • 5 years
General disorders PELVIC MASS	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
General disorders PYREXIA	0.68% 9/1322 • 5 years	0.44% 3/686 • 5 years
General disorders SPINAL PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders SUDDEN CARDIAC DEATH	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
General disorders SURGICAL FAILURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders SWELLING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
General disorders SYSTEMIC INFLAMMATORY RESPONSE SYNDROME	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
General disorders THROMBOSIS IN DEVICE	1.1% 14/1322 • 5 years	0.87% 6/686 • 5 years
Hepatobiliary disorders BILE DUCT STONE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders BILIARY COLIC	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Hepatobiliary disorders CHOLANGITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders CHOLECYSTITIS	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Hepatobiliary disorders CHOLECYSTITIS ACUTE	0.15% 2/1322 • 5 years	0.58% 4/686 • 5 years
Hepatobiliary disorders CHOLECYSTITIS CHRONIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders CHOLELITHIASIS	0.91% 12/1322 • 5 years	0.87% 6/686 • 5 years
Hepatobiliary disorders GALLBLADDER DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders HEPATIC LESION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Hepatobiliary disorders HEPATIC STEATOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders HEPATOMEGALY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Hepatobiliary disorders ISCHAEMIC HEPATITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Hepatobiliary disorders PORTAL VEIN THROMBOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Immune system disorders ALLERGY TO ARTHROPOD STING	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Immune system disorders ANAPHYLACTIC REACTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Immune system disorders CONTRAST MEDIA ALLERGY	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Immune system disorders DRUG HYPERSENSITIVITY	0.38% 5/1322 • 5 years	0.58% 4/686 • 5 years
Immune system disorders FOOD ALLERGY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Immune system disorders HYPERSENSITIVITY	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Immune system disorders SEASONAL ALLERGY	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations ABDOMINAL ABSCESS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations ABDOMINAL INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ABSCESS NECK	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ACUTE SINUSITIS	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations ACUTE TONSILLITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations APPENDICITIS	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations APPENDICITIS PERFORATED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ARTERIOVENOUS GRAFT SITE INFECTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations ARTHRITIS BACTERIAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ARTHRITIS INFECTIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations BACTERAEMIA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations BACTERIAL DISEASE CARRIER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations BACTERIAL INFECTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations BACTERIAL SEPSIS	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations BREAST ABSCESS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations BREAST CELLULITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations BRONCHITIS	2.6% 34/1322 • 5 years	3.1% 21/686 • 5 years
Infections and infestations BRONCHITIS VIRAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations BRONCHOPNEUMONIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations CARBUNCLE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations CATHETER SITE ABSCESS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations CATHETER SITE CELLULITIS	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations CATHETER SITE INFECTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations CELLULITIS	1.1% 15/1322 • 5 years	2.0% 14/686 • 5 years
Infections and infestations CHOLECYSTITIS INFECTIVE	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations CLOSTRIDIAL INFECTION	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations CLOSTRIDIUM DIFFICILE COLITIS	0.23% 3/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations CYSTITIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations DIABETIC FOOT INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations DIVERTICULITIS	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations EAR INFECTION	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ENDOCARDITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ENTEROCOCCAL SEPSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations ESCHERICHIA BACTERAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ESCHERICHIA URINARY TRACT INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations EYELID INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations FOLLICULITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations FUNGAL INFECTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations FURUNCLE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations GANGRENE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations GASTROENTERITIS	0.76% 10/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations GASTROENTERITIS VIRAL	0.30% 4/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations GENITAL INFECTION FEMALE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations GROIN ABSCESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations HELICOBACTER INFECTION	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations HEPATITIS C	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations HERPES ZOSTER	0.53% 7/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations HERPES ZOSTER OPHTHALMIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations HIV INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations IMPLANT SITE INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations INFECTED DERMAL CYST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations INFECTED SKIN ULCER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations INFLUENZA	0.61% 8/1322 • 5 years	1.2% 8/686 • 5 years
Infections and infestations KIDNEY INFECTION	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations LARYNGITIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations LOBAR PNEUMONIA	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations LOCALISED INFECTION	0.00% 0/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations LUNG ABSCESS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations MENINGITIS ASEPTIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations METAPNEUMOVIRUS INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations MYCOBACTERIUM ABSCESSUS INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations NASOPHARYNGITIS	0.45% 6/1322 • 5 years	0.73% 5/686 • 5 years
Infections and infestations ONYCHOMYCOSIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ORAL FUNGAL INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations ORCHITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations OSTEOMYELITIS	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
Infections and infestations OTITIS EXTERNA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations OTITIS MEDIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations OTITIS MEDIA ACUTE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PARONYCHIA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PERITONITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations PERITONSILLAR ABSCESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PHARYNGITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PHARYNGITIS STREPTOCOCCAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations PILONIDAL CYST	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations PNEUMONIA	2.5% 33/1322 • 5 years	3.9% 27/686 • 5 years
Infections and infestations PNEUMONIA ADENOVIRAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA BACTERIAL	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA NECROTISING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA PRIMARY ATYPICAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PNEUMONIA STAPHYLOCOCCAL	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations POST PROCEDURAL CELLULITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations POST PROCEDURAL INFECTION	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations POST PROCEDURAL PNEUMONIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations POSTOPERATIVE WOUND INFECTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations PROSTATE INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations PYELONEPHRITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations RESPIRATORY SYNCYTIAL VIRUS INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations RESPIRATORY TRACT INFECTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations SEPSIS	1.1% 15/1322 • 5 years	1.5% 10/686 • 5 years
Infections and infestations SEPSIS SYNDROME	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations SEPTIC ENCEPHALOPATHY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations SEPTIC SHOCK	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations SINUSITIS	0.83% 11/1322 • 5 years	1.5% 10/686 • 5 years
Infections and infestations SPINAL CORD INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations STAPHYLOCOCCAL BACTERAEMIA	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations STAPHYLOCOCCAL INFECTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations SUBCUTANEOUS ABSCESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations TINEA PEDIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Infections and infestations TOOTH ABSCESS	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	1.9% 25/1322 • 5 years	0.87% 6/686 • 5 years
Infections and infestations URINARY TRACT INFECTION	2.4% 32/1322 • 5 years	3.4% 23/686 • 5 years
Infections and infestations URINARY TRACT INFECTION BACTERIAL	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations UROSEPSIS	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
Infections and infestations VIRAL INFECTION	0.30% 4/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations VIRAL LABYRINTHITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations VIRAL UPPER RESPIRATORY TRACT INFECTION	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Infections and infestations WOUND INFECTION	0.15% 2/1322 • 5 years	0.44% 3/686 • 5 years
Infections and infestations WOUND INFECTION BACTERIAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Infections and infestations WOUND INFECTION STAPHYLOCOCCAL	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications ACCIDENT	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ACCIDENTAL OVERDOSE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications ACETABULUM FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ALCOHOL POISONING	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications ANAEMIA POSTOPERATIVE	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Injury, poisoning and procedural complications ANIMAL BITE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ANKLE FRACTURE	0.08% 1/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications ANXIETY POSTOPERATIVE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ARTHROPOD BITE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications ARTHROPOD STING	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ASBESTOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications AVULSION FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications BURNS THIRD DEGREE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CARDIAC FUNCTION DISTURBANCE POSTOPERATIVE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CARDIAC PROCEDURE COMPLICATION	0.30% 4/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications CATHETER SITE HAEMATOMA	0.76% 10/1322 • 5 years	1.2% 8/686 • 5 years
Injury, poisoning and procedural complications CEREBRAL HAEMORRHAGE TRAUMATIC	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications CLAVICLE FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications COLON INJURY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications CONCUSSION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CONTRAST MEDIA ALLERGY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CONTUSION	1.9% 25/1322 • 5 years	0.87% 6/686 • 5 years
Injury, poisoning and procedural complications CORNEAL ABRASION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CORONARY ARTERY RESTENOSIS	3.9% 51/1322 • 5 years	2.2% 15/686 • 5 years
Injury, poisoning and procedural complications CRANIOCEREBRAL INJURY	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications CYSTITIS RADIATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications DEEP VEIN THROMBOSIS POSTOPERATIVE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications DRUG ADMINISTRATION ERROR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications EXCORIATION	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications EXPOSURE TO TOXIC AGENT	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications FACIAL BONES FRACTURE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications FALL	2.1% 28/1322 • 5 years	2.9% 20/686 • 5 years
Injury, poisoning and procedural complications FEMORAL NECK FRACTURE	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications FEMUR FRACTURE	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications FOOT FRACTURE	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications FOREIGN BODY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications GASTROINTESTINAL ANASTOMOTIC LEAK	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications HAEMATURIA TRAUMATIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications HAND FRACTURE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications HEAD INJURY	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications HIP FRACTURE	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications HUMERUS FRACTURE	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications ILIOTIBIAL BAND SYNDROME	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications IN-STENT ARTERIAL RESTENOSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications IN-STENT CORONARY ARTERY RESTENOSIS	0.61% 8/1322 • 5 years	0.87% 6/686 • 5 years
Injury, poisoning and procedural complications INCISION SITE PRURITUS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications INCISIONAL HERNIA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications INJURY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications JOINT DISLOCATION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications JOINT INJURY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications LACERATION	0.53% 7/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications LIGAMENT RUPTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications LIGAMENT SPRAIN	0.08% 1/1322 • 5 years	0.87% 6/686 • 5 years
Injury, poisoning and procedural complications LIMB INJURY	0.23% 3/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications LIMB TRAUMATIC AMPUTATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications LOWER LIMB FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications MENISCUS LESION	0.61% 8/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications MOUTH INJURY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications MULTIPLE FRACTURES	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications MULTIPLE INJURIES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications MUSCLE RUPTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications MUSCLE STRAIN	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications PELVIC FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PERIORBITAL HAEMATOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PLAQUE SHIFT	0.30% 4/1322 • 5 years	0.87% 6/686 • 5 years
Injury, poisoning and procedural complications POST CONCUSSION SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL CONSTIPATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL DISCOMFORT	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL HAEMATOMA	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL HAEMORRHAGE	0.45% 6/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL MYOCARDIAL INFARCTION	0.91% 12/1322 • 5 years	1.0% 7/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL STROKE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications POST PROCEDURAL SWELLING	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications POST-TRAUMATIC NECK SYNDROME	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications POST-TRAUMATIC PAIN	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications POSTOPERATIVE ADHESION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications POSTOPERATIVE FEVER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL COMPLICATION	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL DIZZINESS	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL HEADACHE	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL HYPERTENSION	0.76% 10/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL HYPOTENSION	0.98% 13/1322 • 5 years	1.0% 7/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL NAUSEA	0.61% 8/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL PAIN	0.23% 3/1322 • 5 years	0.44% 3/686 • 5 years
Injury, poisoning and procedural complications PROCEDURAL VOMITING	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications RADIUS FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications RESPIRATORY FUME INHALATION DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications RIB FRACTURE	0.30% 4/1322 • 5 years	0.44% 3/686 • 5 years
Injury, poisoning and procedural complications ROAD TRAFFIC ACCIDENT	0.76% 10/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications SCAPULA FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SEROMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SKULL FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SNAKE BITE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SOFT TISSUE INJURY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications SPINAL COMPRESSION FRACTURE	0.45% 6/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications SPINAL FRACTURE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications SPLENIC RUPTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications STERNAL FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications SUBDURAL HAEMATOMA	0.45% 6/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications SUTURE RELATED COMPLICATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications TENDON INJURY	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications TENDON RUPTURE	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications THERMAL BURN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications THORACIC VERTEBRAL FRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications TIBIA FRACTURE	0.00% 0/1322 • 5 years	0.58% 4/686 • 5 years
Injury, poisoning and procedural complications TOXICITY TO VARIOUS AGENTS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications TRAUMATIC HAEMATOMA	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Injury, poisoning and procedural complications TRAUMATIC HAEMORRHAGE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications ULNA FRACTURE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications UPPER LIMB FRACTURE	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications URINARY RETENTION POSTOPERATIVE	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications VASCULAR ACCESS COMPLICATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications VASCULAR GRAFT OCCLUSION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications VASCULAR PSEUDOANEURYSM	0.76% 10/1322 • 5 years	0.87% 6/686 • 5 years
Injury, poisoning and procedural complications WOUND	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications WOUND EVISCERATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Injury, poisoning and procedural complications WOUND HAEMORRHAGE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Injury, poisoning and procedural complications WRIST FRACTURE	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Investigations ALANINE AMINOTRANSFERASE INCREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations ANGIOGRAM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations ARTERIOGRAM CORONARY ABNORMAL	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Investigations BIOPSY LUNG	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD ALKALINE PHOSPHATASE INCREASED	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD CREATINE INCREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD CREATINE PHOSPHOKINASE INCREASED	0.91% 12/1322 • 5 years	1.2% 8/686 • 5 years
Investigations BLOOD CREATINE PHOSPHOKINASE MB INCREASED	11.6% 153/1322 • 5 years	10.5% 72/686 • 5 years
Investigations BLOOD CREATININE INCREASED	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Investigations BLOOD GLUCOSE DECREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD GLUCOSE INCREASED	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD HOMOCYSTEINE INCREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD IRON DECREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD MAGNESIUM DECREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD POTASSIUM DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD PRESSURE DECREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD PRESSURE INCREASED	0.91% 12/1322 • 5 years	0.58% 4/686 • 5 years
Investigations BLOOD PRESSURE ORTHOSTATIC ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD PRESSURE SYSTOLIC INCREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD TESTOSTERONE DECREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD THYROID STIMULATING HORMONE DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD TRIGLYCERIDES INCREASED	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BLOOD URIC ACID INCREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BLOOD URINE PRESENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations BONE DENSITY ABNORMAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations BREATH SOUNDS ABNORMAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations CARDIAC ENZYMES INCREASED	7.9% 104/1322 • 5 years	6.6% 45/686 • 5 years
Investigations CARDIAC MURMUR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations CARDIAC STRESS TEST ABNORMAL	0.68% 9/1322 • 5 years	0.44% 3/686 • 5 years
Investigations CAROTID BRUIT	0.53% 7/1322 • 5 years	0.44% 3/686 • 5 years
Investigations CATHETERISATION CARDIAC	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations CLOSTRIDIUM TEST POSITIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations COMPUTERISED TOMOGRAM ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations COMPUTERISED TOMOGRAM THORAX ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations ECHOCARDIOGRAM ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations EJECTION FRACTION ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations EJECTION FRACTION DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations ELECTROCARDIOGRAM ABNORMAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations ELECTROCARDIOGRAM CHANGE	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Investigations ELECTROCARDIOGRAM QT PROLONGED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations ELECTROCARDIOGRAM ST SEGMENT ABNORMAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations ELECTROCARDIOGRAM ST SEGMENT ELEVATION	0.61% 8/1322 • 5 years	0.00% 0/686 • 5 years
Investigations ELECTROCARDIOGRAM ST-T CHANGE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations FEMORAL BRUIT	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations GLOMERULAR FILTRATION RATE DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations GLYCOSYLATED HAEMOGLOBIN INCREASED	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Investigations HAEMOGLOBIN DECREASED	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Investigations HEART RATE DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations HEART RATE INCREASED	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Investigations HEART RATE IRREGULAR	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Investigations HELICOBACTER TEST POSITIVE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations HEPATIC ENZYME INCREASED	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Investigations LIPIDS ABNORMAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations LIVER FUNCTION TEST ABNORMAL	0.15% 2/1322 • 5 years	0.58% 4/686 • 5 years
Investigations METABOLIC FUNCTION TEST ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations OCCULT BLOOD POSITIVE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Investigations OXYGEN CONSUMPTION INCREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations PROSTATIC SPECIFIC ANTIGEN INCREASED	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Investigations RED BLOOD CELL COUNT DECREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations RED BLOOD CELL SEDIMENTATION RATE INCREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations RENAL FUNCTION TEST ABNORMAL	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Investigations THYROID FUNCTION TEST ABNORMAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations TROPONIN I INCREASED	1.8% 24/1322 • 5 years	1.5% 10/686 • 5 years
Investigations TROPONIN INCREASED	3.8% 50/1322 • 5 years	2.9% 20/686 • 5 years
Investigations TROPONIN T INCREASED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Investigations URINE LEUKOCYTE ESTERASE POSITIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations VITAMIN B12 DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Investigations VITAMIN D DECREASED	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Investigations WEIGHT DECREASED	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Investigations WEIGHT INCREASED	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Investigations WHITE BLOOD CELL COUNT INCREASED	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders DECREASED APPETITE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders DEHYDRATION	0.83% 11/1322 • 5 years	1.6% 11/686 • 5 years
Metabolism and nutrition disorders DIABETES MELLITUS	0.68% 9/1322 • 5 years	0.44% 3/686 • 5 years
Metabolism and nutrition disorders DIABETES MELLITUS INADEQUATE CONTROL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders DIABETIC KETOACIDOSIS	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders FAILURE TO THRIVE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders FLUID OVERLOAD	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Metabolism and nutrition disorders FLUID RETENTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders GOUT	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Metabolism and nutrition disorders HYPERGLYCAEMIA	1.1% 14/1322 • 5 years	1.0% 7/686 • 5 years
Metabolism and nutrition disorders HYPERKALAEMIA	0.30% 4/1322 • 5 years	0.73% 5/686 • 5 years
Metabolism and nutrition disorders HYPERLIPIDAEMIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders HYPERURICAEMIA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders HYPOALBUMINAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders HYPOCALCAEMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders HYPOGLYCAEMIA	0.76% 10/1322 • 5 years	0.44% 3/686 • 5 years
Metabolism and nutrition disorders HYPOKALAEMIA	1.1% 15/1322 • 5 years	1.6% 11/686 • 5 years
Metabolism and nutrition disorders HYPOMAGNESAEMIA	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Metabolism and nutrition disorders HYPONATRAEMIA	0.61% 8/1322 • 5 years	0.73% 5/686 • 5 years
Metabolism and nutrition disorders HYPOVOLAEMIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders IMPAIRED FASTING GLUCOSE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders LACTIC ACIDOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders METABOLIC ACIDOSIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Metabolism and nutrition disorders OBESITY	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
Metabolism and nutrition disorders TYPE 2 DIABETES MELLITUS	0.38% 5/1322 • 5 years	0.58% 4/686 • 5 years
Metabolism and nutrition disorders VITAMIN B COMPLEX DEFICIENCY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Metabolism and nutrition disorders VITAMIN D DEFICIENCY	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders ARTHRALGIA	2.0% 27/1322 • 5 years	2.3% 16/686 • 5 years
Musculoskeletal and connective tissue disorders ARTHRITIS	0.61% 8/1322 • 5 years	0.73% 5/686 • 5 years
Musculoskeletal and connective tissue disorders ARTHROFIBROSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders BACK PAIN	4.2% 55/1322 • 5 years	4.1% 28/686 • 5 years
Musculoskeletal and connective tissue disorders BONE LESION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders BONE PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders BURSITIS	0.30% 4/1322 • 5 years	0.58% 4/686 • 5 years
Musculoskeletal and connective tissue disorders CERVICAL SPINAL STENOSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders CHONDROCALCINOSIS PYROPHOSPHATE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders COSTOCHONDRITIS	0.45% 6/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders DUPUYTREN'S CONTRACTURE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders EXOSTOSIS	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders FLANK PAIN	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Musculoskeletal and connective tissue disorders FOOT DEFORMITY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders FRACTURE NONUNION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders INTERVERTEBRAL DISC DEGENERATION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders INTERVERTEBRAL DISC PROTRUSION	0.68% 9/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders JOINT EFFUSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders JOINT STIFFNESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders JOINT SWELLING	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders LIMB DISCOMFORT	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders LUMBAR SPINAL STENOSIS	0.53% 7/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders MOBILITY DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCLE SPASMS	0.76% 10/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULAR WEAKNESS	0.45% 6/1322 • 5 years	0.58% 4/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL CHEST PAIN	1.6% 21/1322 • 5 years	1.0% 7/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL DISCOMFORT	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL PAIN	1.4% 18/1322 • 5 years	2.3% 16/686 • 5 years
Musculoskeletal and connective tissue disorders MYALGIA	0.91% 12/1322 • 5 years	1.2% 8/686 • 5 years
Musculoskeletal and connective tissue disorders MYOSITIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders NECK PAIN	0.53% 7/1322 • 5 years	0.73% 5/686 • 5 years
Musculoskeletal and connective tissue disorders OSTEOARTHRITIS	2.3% 30/1322 • 5 years	2.6% 18/686 • 5 years
Musculoskeletal and connective tissue disorders OSTEOPENIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders OSTEOPOROSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	3.0% 40/1322 • 5 years	2.2% 15/686 • 5 years
Musculoskeletal and connective tissue disorders PAIN IN JAW	0.53% 7/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders PERIARTHRITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders PLANTAR FASCIITIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders POLYMYALGIA RHEUMATICA	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders RHABDOMYOLYSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders RHEUMATOID ARTHRITIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders ROTATOR CUFF SYNDROME	0.61% 8/1322 • 5 years	0.58% 4/686 • 5 years
Musculoskeletal and connective tissue disorders SACROILIITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders SPINAL OSTEOARTHRITIS	0.45% 6/1322 • 5 years	0.58% 4/686 • 5 years
Musculoskeletal and connective tissue disorders SPONDYLITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders SPONDYLOLISTHESIS	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Musculoskeletal and connective tissue disorders SYNOVIAL CYST	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders SYSTEMIC LUPUS ERYTHEMATOSUS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders TENDINOUS CONTRACTURE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders TENDONITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders TENOSYNOVITIS STENOSANS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Musculoskeletal and connective tissue disorders TRIGGER FINGER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Musculoskeletal and connective tissue disorders VERTEBRAL FORAMINAL STENOSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ACOUSTIC NEUROMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ACUTE MYELOID LEUKAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ACUTE MYELOID LEUKAEMIA RECURRENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ADENOCARCINOMA	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ADENOCARCINOMA PANCREAS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) B-CELL LYMPHOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) B-CELL LYMPHOMA STAGE IV	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BASAL CELL CARCINOMA	0.45% 6/1322 • 5 years	1.0% 7/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BENIGN BREAST NEOPLASM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BENIGN OVARIAN TUMOUR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BILE DUCT CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER CANCER	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER CANCER RECURRENT	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER CANCER STAGE IV	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BLADDER NEOPLASM	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BRAIN NEOPLASM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BREAST CANCER	0.38% 5/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) BREAST CANCER STAGE III	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) CERVIX CARCINOMA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) CHRONIC LYMPHOCYTIC LEUKAEMIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) COLON ADENOMA	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) COLON CANCER	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) DIFFUSE LARGE B-CELL LYMPHOMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) GASTRIC CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) GLIOBLASTOMA	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HAEMANGIOMA OF SPLEEN	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HEAD AND NECK CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HEAD AND NECK CANCER METASTATIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HEPATIC CANCER METASTATIC	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HEPATIC NEOPLASM MALIGNANT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) HYPOPHARYNGEAL CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LARYNGEAL CANCER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LEUKAEMIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LEUKAEMIA RECURRENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LIP AND/OR ORAL CAVITY CANCER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LIPOMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG ADENOCARCINOMA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG CANCER METASTATIC	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG NEOPLASM	0.38% 5/1322 • 5 years	0.87% 6/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG NEOPLASM MALIGNANT	0.53% 7/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG SQUAMOUS CELL CARCINOMA STAGE III	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) LYMPHOMA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MALIGNANT MELANOMA	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) MELANOCYTIC NAEVUS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OESOPHAGEAL CARCINOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ORAL NEOPLASM	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OROPHARYNGEAL CANCER STAGE UNSPECIFIED	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OVARIAN CANCER METASTATIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) OVARIAN EPITHELIAL CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PANCREATIC CARCINOMA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PERICARDIAL EFFUSION MALIGNANT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PROSTATE CANCER	0.83% 11/1322 • 5 years	0.58% 4/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PROSTATE CANCER RECURRENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RECTAL CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL CANCER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL CELL CARCINOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL HAEMANGIOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RENAL NEOPLASM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SEBORRHOEIC KERATOSIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SINONASAL PAPILLOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SKIN CANCER	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SKIN PAPILLOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SMALL CELL LUNG CANCER LIMITED STAGE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SMALL CELL LUNG CANCER STAGE UNSPECIFIED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SQUAMOUS CELL CARCINOMA	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) SQUAMOUS CELL CARCINOMA OF SKIN	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) THYROID NEOPLASM	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) TRANSITIONAL CELL CARCINOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) URETERIC CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) UTERINE CANCER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) UTERINE LEIOMYOMA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Neoplasms benign, malignant and unspecified (incl cysts and polyps) VULVAL CANCER STAGE 0	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders ALTERED STATE OF CONSCIOUSNESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders AMNESIA	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders APHASIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders ARACHNOIDITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders ATAXIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders AUTONOMIC NERVOUS SYSTEM IMBALANCE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders BALANCE DISORDER	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders BURNING SENSATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CAROTID ARTERY DISEASE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders CAROTID ARTERY STENOSIS	1.1% 15/1322 • 5 years	1.3% 9/686 • 5 years
Nervous system disorders CARPAL TUNNEL SYNDROME	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders CAUDA EQUINA SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CENTRAL NERVOUS SYSTEM LESION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CEREBELLAR INFARCTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CEREBRAL HAEMORRHAGE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders CEREBRAL INFARCTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders CEREBROVASCULAR ACCIDENT	1.5% 20/1322 • 5 years	2.2% 15/686 • 5 years
Nervous system disorders CEREBROVASCULAR DISORDER	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders CERVICOBRACHIAL SYNDROME	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders COMPLICATED MIGRAINE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders CONVULSION	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders CUBITAL TUNNEL SYNDROME	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders DEMENTIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders DIABETIC NEUROPATHY	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders DIZZINESS	4.4% 58/1322 • 5 years	3.9% 27/686 • 5 years
Nervous system disorders DIZZINESS EXERTIONAL	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders DIZZINESS POSTURAL	0.53% 7/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders DYSAESTHESIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders DYSARTHRIA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders DYSGEUSIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders EMBOLIC STROKE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders ENCEPHALOPATHY	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders ESSENTIAL TREMOR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders GUILLAIN-BARRE SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HAEMORRHAGE INTRACRANIAL	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders HAEMORRHAGIC STROKE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HEAD DISCOMFORT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HEAD TITUBATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HEADACHE	2.1% 28/1322 • 5 years	2.8% 19/686 • 5 years
Nervous system disorders HEMIPARESIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders HEMIPLEGIC MIGRAINE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HEPATIC ENCEPHALOPATHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders HYPOAESTHESIA	0.98% 13/1322 • 5 years	1.2% 8/686 • 5 years
Nervous system disorders HYPOXIC-ISCHAEMIC ENCEPHALOPATHYv	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders IIIRD NERVE PARALYSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders INTENTION TREMOR	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders ISCHAEMIC STROKE	0.45% 6/1322 • 5 years	0.44% 3/686 • 5 years
Nervous system disorders LACUNAR INFARCTION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders LATERAL MEDULLARY SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders LETHARGY	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders LOSS OF CONSCIOUSNESS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders LUMBAR RADICULOPATHY	0.15% 2/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders MEMORY IMPAIRMENT	0.45% 6/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders MENTAL IMPAIRMENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders METABOLIC ENCEPHALOPATHY	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders MIGRAINE	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders MYELOMALACIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders NERVE COMPRESSION	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders NEURALGIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders NEUROLOGICAL SYMPTOM	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders NEUROPATHY PERIPHERAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders NYSTAGMUS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders PARAESTHESIA	0.61% 8/1322 • 5 years	0.58% 4/686 • 5 years
Nervous system disorders POLYNEUROPATHY ALCOHOLIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders POST-TRAUMATIC HEADACHE	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders PRESYNCOPE	2.0% 26/1322 • 5 years	1.2% 8/686 • 5 years
Nervous system disorders RADICULITIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders RADICULITIS CERVICAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders SCIATICA	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders SENSORY DISTURBANCE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders SOMNOLENCE	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders SPEECH DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders SPONDYLITIC MYELOPATHY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders SUBARACHNOID HAEMORRHAGE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders SUBDURAL HYGROMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders SYNCOPE	3.0% 40/1322 • 5 years	3.2% 22/686 • 5 years
Nervous system disorders THALAMIC INFARCTION	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders THROMBOTIC STROKE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders TRANSIENT GLOBAL AMNESIA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders TRANSIENT ISCHAEMIC ATTACK	1.3% 17/1322 • 5 years	1.2% 8/686 • 5 years
Nervous system disorders TREMOR	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Nervous system disorders UNRESPONSIVE TO STIMULI	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Nervous system disorders URAEMIC ENCEPHALOPATHY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders VERTEBRAL ARTERY OCCLUSION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Nervous system disorders VITH NERVE PARALYSIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders ACUTE STRESS DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders ADJUSTMENT DISORDER WITH MIXED DISTURBANCE OF EMOTION AND CONDUCT	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders AFFECTIVE DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders ALCOHOL ABUSE	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders ALCOHOL PROBLEM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders ALCOHOL WITHDRAWAL SYNDROME	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders ANXIETY	1.5% 20/1322 • 5 years	1.0% 7/686 • 5 years
Psychiatric disorders ANXIETY DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders BIPOLAR DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders BIPOLAR I DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders COMPLETED SUICIDE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders CONFUSIONAL STATE	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Psychiatric disorders DELIRIUM	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders DELIRIUM TREMENS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders DEPRESSED MOOD	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders DEPRESSION	1.3% 17/1322 • 5 years	0.44% 3/686 • 5 years
Psychiatric disorders DEPRESSION SUICIDAL	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders HALLUCINATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders HALLUCINATION, VISUAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders INSOMNIA	0.30% 4/1322 • 5 years	0.44% 3/686 • 5 years
Psychiatric disorders INTENTIONAL SELF-INJURY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders MAJOR DEPRESSION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders MENTAL STATUS CHANGES	0.45% 6/1322 • 5 years	0.29% 2/686 • 5 years
Psychiatric disorders OBSESSIVE-COMPULSIVE DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders PANIC ATTACK	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Psychiatric disorders STRESS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Psychiatric disorders SUICIDAL IDEATION	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Renal and urinary disorders BLADDER DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Renal and urinary disorders CALCULUS URETERIC	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Renal and urinary disorders CYSTITIS HAEMORRHAGIC	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders CYSTITIS INTERSTITIAL	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders DYSURIA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders HAEMATURIA	0.98% 13/1322 • 5 years	1.6% 11/686 • 5 years
Renal and urinary disorders HYDRONEPHROSIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Renal and urinary disorders HYPERTONIC BLADDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders MICROALBUMINURIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders NEPHROLITHIASIS	1.4% 18/1322 • 5 years	1.5% 10/686 • 5 years
Renal and urinary disorders NOCTURIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders POLLAKIURIA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders RENAL ARTERY STENOSIS	0.08% 1/1322 • 5 years	0.44% 3/686 • 5 years
Renal and urinary disorders RENAL CYST	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Renal and urinary disorders RENAL DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders RENAL FAILURE	0.61% 8/1322 • 5 years	0.73% 5/686 • 5 years
Renal and urinary disorders RENAL FAILURE ACUTE	1.3% 17/1322 • 5 years	2.0% 14/686 • 5 years
Renal and urinary disorders RENAL FAILURE CHRONIC	0.23% 3/1322 • 5 years	0.73% 5/686 • 5 years
Renal and urinary disorders RENAL IMPAIRMENT	0.08% 1/1322 • 5 years	0.29% 2/686 • 5 years
Renal and urinary disorders RENAL TUBULAR NECROSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders STRESS URINARY INCONTINENCE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders URETHRAL STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders URINARY HESITATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders URINARY INCONTINENCE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Renal and urinary disorders URINARY RETENTION	0.91% 12/1322 • 5 years	0.44% 3/686 • 5 years
Renal and urinary disorders URINE FLOW DECREASED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders BENIGN PROSTATIC HYPERPLASIA	0.53% 7/1322 • 5 years	0.73% 5/686 • 5 years
Reproductive system and breast disorders BREAST CALCIFICATIONS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders BREAST MASS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders BREAST PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders DYSFUNCTIONAL UTERINE BLEEDING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders EPIDIDYMAL CYST	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Reproductive system and breast disorders FALLOPIAN TUBE CYST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders FEMALE GENITAL TRACT FISTULA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders HAEMATOSPERMIA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders MENORRHAGIA	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Reproductive system and breast disorders PELVIC HAEMATOMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders PENILE HAEMORRHAGE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders POLYCYSTIC OVARIES	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders PROSTATITIS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders PROSTATOMEGALY	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Reproductive system and breast disorders SEXUAL DYSFUNCTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders SPERMATOCELE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders TESTICULAR PAIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders UTERINE POLYP	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Reproductive system and breast disorders VAGINAL HAEMORRHAGE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Reproductive system and breast disorders VULVA CYST	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders ACUTE PULMONARY OEDEMA	0.00% 0/1322 • 5 years	0.58% 4/686 • 5 years
Respiratory, thoracic and mediastinal disorders ACUTE RESPIRATORY FAILURE	1.4% 18/1322 • 5 years	1.0% 7/686 • 5 years
Respiratory, thoracic and mediastinal disorders ALLERGIC GRANULOMATOUS ANGIITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders ASPIRATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders ASTHMA	0.45% 6/1322 • 5 years	0.58% 4/686 • 5 years
Respiratory, thoracic and mediastinal disorders ATELECTASIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders BRONCHIAL HYPERREACTIVITY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders BRONCHITIS CHRONIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders CHOKING	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders CHRONIC OBSTRUCTIVE PULMONARY DISEASE	2.6% 35/1322 • 5 years	2.2% 15/686 • 5 years
Respiratory, thoracic and mediastinal disorders COUGH	1.6% 21/1322 • 5 years	1.7% 12/686 • 5 years
Respiratory, thoracic and mediastinal disorders DYSPHONIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders DYSPNOEA	9.5% 126/1322 • 5 years	8.0% 55/686 • 5 years
Respiratory, thoracic and mediastinal disorders DYSPNOEA EXERTIONAL	3.9% 51/1322 • 5 years	4.8% 33/686 • 5 years
Respiratory, thoracic and mediastinal disorders DYSPNOEA PAROXYSMAL NOCTURNAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders EMPHYSEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders EPISTAXIS	2.0% 26/1322 • 5 years	2.2% 15/686 • 5 years
Respiratory, thoracic and mediastinal disorders HAEMOPTYSIS	0.15% 2/1322 • 5 years	0.73% 5/686 • 5 years
Respiratory, thoracic and mediastinal disorders HYPERVENTILATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders HYPOXIA	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Respiratory, thoracic and mediastinal disorders INTERSTITIAL LUNG DISEASE	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders MEDIASTINAL MASS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders NASAL POLYPS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders NASAL SEPTUM ULCERATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders NON-CARDIOGENIC PULMONARY OEDEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders OBSTRUCTIVE AIRWAYS DISORDER	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders ORGANISING PNEUMONIA	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders OROPHARYNGEAL PAIN	0.30% 4/1322 • 5 years	0.44% 3/686 • 5 years
Respiratory, thoracic and mediastinal disorders ORTHOPNOEA	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders PHARYNGEAL OEDEMA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders PLEURAL EFFUSION	0.68% 9/1322 • 5 years	0.87% 6/686 • 5 years
Respiratory, thoracic and mediastinal disorders PLEURITIC PAIN	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Respiratory, thoracic and mediastinal disorders PNEUMONIA ASPIRATION	0.00% 0/1322 • 5 years	0.58% 4/686 • 5 years
Respiratory, thoracic and mediastinal disorders PNEUMONITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders PNEUMOTHORAX	0.15% 2/1322 • 5 years	0.87% 6/686 • 5 years
Respiratory, thoracic and mediastinal disorders PRODUCTIVE COUGH	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders PULMONARY CONGESTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders PULMONARY EMBOLISM	0.68% 9/1322 • 5 years	1.0% 7/686 • 5 years
Respiratory, thoracic and mediastinal disorders PULMONARY FIBROSIS	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Respiratory, thoracic and mediastinal disorders PULMONARY HYPERTENSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders PULMONARY OEDEMA	0.23% 3/1322 • 5 years	0.29% 2/686 • 5 years
Respiratory, thoracic and mediastinal disorders RESPIRATORY ALKALOSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders RESPIRATORY ARREST	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders RESPIRATORY DISORDER	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders RESPIRATORY FAILURE	1.1% 14/1322 • 5 years	1.2% 8/686 • 5 years
Respiratory, thoracic and mediastinal disorders RHINITIS ALLERGIC	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders RHINORRHOEA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders SINUS CONGESTION	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders SLEEP APNOEA SYNDROME	0.61% 8/1322 • 5 years	0.87% 6/686 • 5 years
Respiratory, thoracic and mediastinal disorders THROAT TIGHTNESS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders TRACHEAL STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders UPPER RESPIRATORY TRACT CONGESTION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Respiratory, thoracic and mediastinal disorders UPPER-AIRWAY COUGH SYNDROME	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Respiratory, thoracic and mediastinal disorders WHEEZING	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders ACTINIC KERATOSIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders ANGIOEDEMA	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders DECUBITUS ULCER	0.23% 3/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders DERMATITIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders DERMATITIS ATOPIC	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders DERMATITIS CONTACT	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders DIABETIC FOOT	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders DRUG ERUPTION	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Skin and subcutaneous tissue disorders ECCHYMOSIS	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders ECZEMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders ERYTHEMA	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders HYPERHIDROSIS	0.38% 5/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders HYPERKERATOSIS	0.00% 0/1322 • 5 years	0.29% 2/686 • 5 years
Skin and subcutaneous tissue disorders INCREASED TENDENCY TO BRUISE	0.68% 9/1322 • 5 years	0.73% 5/686 • 5 years
Skin and subcutaneous tissue disorders INGROWING NAIL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders LICHENOID KERATOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders LIVEDO RETICULARIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders NIGHT SWEATS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders PRECANCEROUS SKIN LESION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders PRURITUS	0.30% 4/1322 • 5 years	0.29% 2/686 • 5 years
Skin and subcutaneous tissue disorders PRURITUS ALLERGIC	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders PSORIASIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders RASH	1.1% 15/1322 • 5 years	1.2% 8/686 • 5 years
Skin and subcutaneous tissue disorders RASH GENERALISED	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders RASH PRURITIC	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Skin and subcutaneous tissue disorders SEBORRHOEIC DERMATITIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders SKIN LESION	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders SKIN ULCER	0.38% 5/1322 • 5 years	0.44% 3/686 • 5 years
Skin and subcutaneous tissue disorders SWELLING FACE	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Skin and subcutaneous tissue disorders URTICARIA	0.30% 4/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures AORTIC ANEURYSM REPAIR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures CARDIAC ABLATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures CARDIAC PACEMAKER BATTERY REPLACEMENT	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures CARDIAC PACEMAKER REPLACEMENT	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures CHOLECYSTECTOMY	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures COLOSTOMY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures CORONARY ARTERY BYPASS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures DENTAL IMPLANTATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures HERNIA HIATUS REPAIR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures HIP ARTHROPLASTY	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures INGUINAL HERNIA REPAIR	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures KNEE ARTHROPLASTY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures LEG AMPUTATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures MEDICAL DEVICE REMOVAL	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures NEPHRECTOMY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures SINUS OPERATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures SPINAL FUSION SURGERY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures TENDON OPERATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures THERAPY CESSATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Surgical and medical procedures TONSILLECTOMY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures TOOTH EXTRACTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Surgical and medical procedures TRANSURETHRAL PROSTATECTOMY	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders ACCELERATED HYPERTENSION	0.30% 4/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders AORTIC ANEURYSM	0.61% 8/1322 • 5 years	0.44% 3/686 • 5 years
Vascular disorders AORTIC DISSECTION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders AORTIC INTRAMURAL HAEMATOMA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders AORTIC STENOSIS	0.30% 4/1322 • 5 years	0.73% 5/686 • 5 years
Vascular disorders ARTERIAL SPASM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders ARTERIOSCLEROSIS	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders ARTERIOVENOUS FISTULA	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders BLEEDING VARICOSE VEIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders BLOOD PRESSURE FLUCTUATION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders BLOOD PRESSURE INADEQUATELY CONTROLLED	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders CIRCULATORY COLLAPSE	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders DEEP VEIN THROMBOSIS	0.91% 12/1322 • 5 years	1.2% 8/686 • 5 years
Vascular disorders ESSENTIAL HYPERTENSION	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders FEMORAL ARTERIAL STENOSIS	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders FEMORAL ARTERY OCCLUSION	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders FLUSHING	0.00% 0/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders HAEMATOMA	0.61% 8/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders HAEMORRHAGE	0.15% 2/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders HOT FLUSH	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders HYPERTENSION	4.5% 60/1322 • 5 years	3.5% 24/686 • 5 years
Vascular disorders HYPERTENSIVE CRISIS	0.53% 7/1322 • 5 years	1.0% 7/686 • 5 years
Vascular disorders HYPOTENSION	2.9% 38/1322 • 5 years	1.9% 13/686 • 5 years
Vascular disorders ILIAC ARTERY OCCLUSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders ILIAC ARTERY STENOSIS	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders INTERMITTENT CLAUDICATION	1.1% 14/1322 • 5 years	1.5% 10/686 • 5 years
Vascular disorders LABILE HYPERTENSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders MALIGNANT HYPERTENSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders ORTHOSTATIC HYPERTENSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders ORTHOSTATIC HYPOTENSION	0.61% 8/1322 • 5 years	0.44% 3/686 • 5 years
Vascular disorders PALLOR	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	0.38% 5/1322 • 5 years	1.5% 10/686 • 5 years
Vascular disorders PERIPHERAL COLDNESS	0.15% 2/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders PERIPHERAL ISCHAEMIA	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders PERIPHERAL VASCULAR DISORDER	0.61% 8/1322 • 5 years	0.87% 6/686 • 5 years
Vascular disorders POOR PERIPHERAL CIRCULATION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders RAYNAUD'S PHENOMENON	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders REPERFUSION INJURY	0.38% 5/1322 • 5 years	0.29% 2/686 • 5 years
Vascular disorders SUBCLAVIAN ARTERY OCCLUSION	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders SUBCLAVIAN ARTERY STENOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders SUBCLAVIAN STEAL SYNDROME	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders THROMBOPHLEBITIS SUPERFICIAL	0.08% 1/1322 • 5 years	0.15% 1/686 • 5 years
Vascular disorders THROMBOSIS	0.23% 3/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders VARICOSE VEIN	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders VASOSPASM	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders VENOUS INSUFFICIENCY	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years
Vascular disorders WEGENER'S GRANULOMATOSIS	0.08% 1/1322 • 5 years	0.00% 0/686 • 5 years

Additional Information

Latania Chura / Project Manager

Abbott Vascular

Phone: 503.935.3002

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: LTE60